



US 20080220450A1

(19) **United States**

(12) **Patent Application Publication**
Harding

(10) **Pub. No.: US 2008/0220450 A1**
(43) **Pub. Date: Sep. 11, 2008**

(54) **POPULATION BASED PREDICTION
METHODS FOR IMMUNE RESPONSE
DETERMINATIONS AND METHODS FOR
VERIFYING IMMUNOLOGICAL RESPONSE
DATA**

Related U.S. Application Data

(60) Provisional application No. 60/565,680, filed on Apr. 26, 2004.

Publication Classification

(75) Inventor: **Fiona A. Harding**, Santa Clara, CA (US)

(51) **Int. Cl.**
G01N 33/53 (2006.01)
C12Q 1/02 (2006.01)
C12Q 1/48 (2006.01)
C12Q 1/34 (2006.01)
C12Q 1/26 (2006.01)
C12Q 1/42 (2006.01)
C12Q 1/40 (2006.01)

Correspondence Address:
GENENCOR INTERNATIONAL, INC.
ATTENTION: LEGAL DEPARTMENT
925 PAGE MILL ROAD
PALO ALTO, CA 94304 (US)

(52) **U.S. Cl.** **435/7.21; 435/29; 435/15; 435/18; 435/25; 435/21; 435/22**

(73) Assignee: **Danisco US, Inc., Genencor Division**, Palo Alto, CA (US)

(57) **ABSTRACT**


The present invention provides means to assess immune response profiles of populations. In particular, the present invention provides means to qualitatively assess the immune response of human populations, wherein the immune response directed against any protein of interest is analyzed. The present invention further provides means to rank proteins based on their relative immunogenicity. In further embodiments, the present invention provides means for verifying immunological response data, as well as means for predicting immune responses directed against any antigen/immunogen. In addition, the present invention provides means to create proteins with reduced immunogenicity for use in various applications.

(21) Appl. No.: **10/591,681**

(22) PCT Filed: **Apr. 25, 2005**

(86) PCT No.: **PCT/US2005/014182**

§ 371 (c)(1),
(2), (4) Date: **Apr. 14, 2008**






FIG. 1






FIG. 2






FIG. 5




FIG. 6




FIG. 7A




FIG. 7B




FIG. 8




FIG. 9






FIG. 10






FIG. 13

Peptide	HLA Association	p	HLA Increased	HLA Decreased	Warmerdam, et al (2002)* Region
5			DQ2		D1 DR3, 7, 2
20	DR2 (15)	p < 0.03	DQ6	DR7	F2 DR1, 4
21			DR6 (13)		C3 DR2, 3, 4, 6, 7, 8
29	DR5 (11)	p < 0.01			n.f.#
36			DR3		D4 DR3, 6
n.f.#					A5 DR2, 5, 6, 8

FIG. 15




FIG. 14A




FIG. 14B




FIG. 16A




FIG. 16B

nM IC₅₀ For Binding To Purified HLA

Protein	DRB1									
	*0101 (DR1)	*0301 (DR3w17)	*0401 (DR4w4)	*0404 (DR4w14)	*0405 (DR4w15)	*0701 (DR7)	*0802 (DR8w2)	*0901 (DR9)	*1101 (DR5w11)	*1201 (DR5w12)
BPN' Y217L .70	6.5	8737	33	5.7	166	154	1711	46	2382	80
BPN' Y217L .109	8.8	--	30	166	37	58	2192	43	3019	1235
B. lentus 157	1065	16,433	4794	7575	6784	724	>16,333	1484	--	--
B. lentus .160	13	--	142	5542	1348	138	2033	164	5554	--

	DRB1		DRB3/4/5			DQ			Degeneracy n/18
	*1302 (DR6w19)	*1501 (DR2w2β1)	*DRB3*0101 (DR52a)	*DRB4*0101 (DRw53)	*DRB5*0101 (DR2w2β2)	DQA1*0501/ DQB1*0201 (DQ2)	DQA1*0301/ DQB1*0301 (DQ3.1)	DQA1*0301/ DQB1*0302 (DQ3.2)	
0.69	21	2010	31	15,689	670	440	2069	12	
9.8	683	119	1071	1024	97	2182	80	11	
2009	865	>9434	>9667	--	6157	6009	5009	2	
559	127	6157	8257	1726	1296	63	1046	7	

FIG. 17




FIG. 18








FIG. 19








FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30A




FIG. 30B




FIG. 31A




FIG. 31B




FIG. 32




FIG. 33




FIG. 34

**POPULATION BASED PREDICTION
METHODS FOR IMMUNE RESPONSE
DETERMINATIONS AND METHODS FOR
VERIFYING IMMUNOLOGICAL RESPONSE
DATA**

FIELD OF THE INVENTION

[0001] The present invention provides means to assess immune response profiles of populations. In particular, the present invention provides means to qualitatively assess the immune response of human populations, wherein the immune response directed against any protein of interest is analyzed. The present invention further provides means to rank proteins based on their relative immunogenicity. In further embodiments, the present invention provides means for verifying immunological response data, as well as means for predicting immune responses directed against any antigen/immunogen. In addition, the present invention provides means to create proteins with reduced immunogenicity for use in various applications.

BACKGROUND OF THE INVENTION

[0002] Proteins have the capacity to induce potentially life-threatening immune responses. This limitation has hindered their widespread use in consumer end-use applications and products. Indeed, this potential to induce immune responses has come to the attention of the U.S. Food and Drug Administration (FDA), resulting in the requirement for immunogenicity testing both prior to and after approval of new protein therapeutics. However, although there are a number of animal models available for assessing immunogenicity, there are no validated methods to discern relative immunogenicity in humans.

[0003] Despite these concerns, the immunogenicity of proteins has long been a concern in the enzyme manufacturing industry. Occupational exposure to proteins has been documented to result in sensitization of industrial and laboratory workers. Sensitization to particular proteins is usually assessed by tests such as the skin-prick test that reveals whether an individual has mounted an immune response to the protein.

[0004] Indeed, occupational exposure to proteins has been documented to result in sensitization of industrial and laboratory workers. In most settings, sensitization is controlled by reducing the level of airborne protein (See, Sarlo and Kirchner, *Curr. Opin. Allergy Clin. Immunol.*, 2:97-101 [2002]; and Schweigert et al., *Clin. Exp. Allergy* 30:1511-1518 [2000]). Occupational exposure guidelines have been implemented that control airborne exposure to proteins. These guidelines, which provide the allowable level of exposure to particular proteins have been useful in reducing the overall number of sensitization events occurring in a given industrial setting. When a new protein is to be manufactured, the establishment of occupational exposure guidelines (OEGs) for the new protein is a matter of serious concern. A commonly accepted method to determine these guidelines is the guinea pig intra-tracheal test (GPIT) (See, Sarlo, *Fundam. Appl. Toxicol.*, 39:44-52 [1997]). In this test, guinea pigs are exposed to the test protein via intra-tracheal instillation for a period of about 10-12 weeks. Serum samples from the animals are taken periodically and tested for their levels of antigen-specific antibody by suitable methods known in the art (e.g., passive cutaneous testing (PCA) for IgG₁ and by micro-

immunodiffusion testing (MID) for precipitating IgG). These results are compared to results obtained from a set of guinea pigs tested with control proteins that have known, effective exposure guidelines (e.g., ALCALASE® enzyme, commercially available from Novo). Determination of serum titers, MID positively and time to response are considered, and a relative potency value is determined. This method has been used successfully to set OEGs for a number of industrial enzymes.

[0005] However, while the GPIT test is useful, it is time consuming and expensive, requiring a number of animals and multiple rounds of testing. Relatively recently, a mouse-based test was established that is reported to reproduce the results obtained in the GPIT, through the use of a less expensive and less cumbersome animal model. The mouse intranasal test (MINT; See, Robinson et al., *Toxicol. Sci.* 43:39-46 [1998]) is used by some companies to set OEG guidelines. However, industry-wide acceptance has not been achieved for this model (for reviews of predictive tests for protein allergenicity, see Robinson et al., *supra*, as well as Kimber et al., (Kimber et al., *Fundam. Appl. Toxicol.*, 33:1-10 [1996]; and Kimber et al., *Toxicol. Sci.*, 48:157-162 [1999]).

[0006] Thus, although animal models are useful, they have limitations. The use of partially outbred guinea pigs in the GPIT necessitates the use of large numbers of animals in order to achieve statistical significance when comparing responses between groups. In addition, inter-experiment variation in control animal responses is very high, which makes potency determinations based on a single set of control responses less convincing. The MINT assay does not suffer from as much variability in antibody responses because the mice used are typically BDF1 mice, a cross between two highly inbred mouse strains. While this additional level of control allows for more robust data analyses, different strains of mice typically return very different potency rankings for similar enzymes (See, Blaikie, *Food Chem. Toxicol.*, 37:897-904 [1999]; and Blaikie and Basketter, *Food Chem. Toxicol.*, 37:889-896 [1999]). This is likely due to the specificity of the immune response in a mouse line that is inbred to express very limited MHC molecules. In addition, while data from an individual lab using the MINT assay may be robust, the MINT assay is also plagued by inter-laboratory differences.

[0007] Significantly, all animal tests suffer from the inability to provide a suitable representation of the immune response to a given protein in humans. Inbred strains of mice present peptide molecules with the specificity conferred by their murine MHC molecules. Human HLA molecules, while highly related to mouse MHC molecules, do not have identical peptide specificities. Furthermore, inbred mouse strains have been selected for expression of a single I-A and/or I-E molecule, a situation that very rarely occurs in the highly outbred human population. In addition, the mouse immune system has a number of properties which are not found in humans (e.g., the Th1 versus Th2 paradigm that has been described in mice is much less clear in humans). For example, in humans, there is plasticity in Th1 and Th2 phenotypes that can be explained by a genetic inconsistency in the IFN-alpha gene. In contrast, in mice, the Th1 and Th2 phenotypes are not dynamic, due to an insertion in the IFN-alpha gene in these animals (See, Farrar, *Nat. Immunol.*, 1:65-69 [2000]). In addition, humans express HLA class II molecules on activated T cells, while mice do not. Furthermore, human donors typically carry endogenous viruses, and often have subclini-

cal infections, while laboratory mice are typically maintained in a specific-pathogen free (SPF) environment. Another concern is that the C57Bl/6 mouse strain, a popular background for the creation of transgenic mouse models, carries a defined antigen-processing defect that makes comparisons to human derived data of questionable reliability (Kim and Jang, *Eur. J. Immunol.*, 22:775-782 [1992]). Human HLA transgenic mice have become available for application to the mechanistic study of human immune responses (See, Boyton and Altmann, *Clin. Exp. Immunol.*, 127:4-11 [2002]; Black et al., *J. Immunol.*, 169:5595-5600 [2002]; Raju et al., *Hum. Immunol.*, 63:237-247 [2002]; and Das et al., *Rev. Immunogenet.*, 2:105-114 [2000]). However, the use of these animals is limited, as HLA transgenic mice suffer from species-specific immune system complexities. In addition, at least some of the methods used to construct these mice do not allow for accurate analysis of peptide-specific responses, as expression of the HLA transgenes is not correctly regulated. HLA transgenic mice are often used for mapping studies when expressing a single HLA molecule, a situation not found in humans. This is especially of note for HLA-DQ transgenic mice where cross-pairing between different HLA-DQ alleles has been shown to create new peptide presentation specificities (See, Krco et al., *J. Immunol.*, 163:1661-1665 [1999]). Thus, despite advances in the determination, assessment, and comparisons of the immunogenicity of proteins, there remains a need in the art for simple, reliable and reproducible methods to make such determinations.

[0008] Likewise, the application of proteins to therapeutic, industrial and nutritional uses is limited by the potential for inducing or exacerbating deleterious immune responses. This potential is especially of concern for the use of recombinant human-derived proteins. Indeed, recombinant human-derived proteins have been demonstrated to induce immune responses directed at self-proteins, resulting in the development of autoimmunity (Li et al., *Blood* 98:3241-3248 [2001]; and Casadell et al., *N. Eng. J. Med.*, 346:469-475 [2002]). Subsequent reactivation of the immune system after unintended induction of immune responses to industrial or food proteins can be minimized by avoidance. However, this is not the case with human-derived therapeutic proteins. The selection and/or creation of reduced immunogenic protein variants is therefore necessary to improve safety and efficacy of administered proteins. The selection of a naturally occurring hypo-immunogenic protein isomer is an option where several related molecules with similar activities exist. Unfortunately, this is not an option for many therapeutic proteins. Thus, there is a long-felt need in the art for means to produce hypo-immunogenic proteins suitable for use as therapeutics and for other applications.

SUMMARY OF THE INVENTION

[0009] The present invention provides means to assess immune response profiles of populations. In particular, the present invention provides means to qualitatively assess the immune response of human populations, wherein the immune response directed against any protein of interest is analyzed. The present invention further provides means to rank proteins based on their relative immunogenicity. In further embodiments, the present invention provides means for verifying immunological response data, as well as means for predicting immune responses directed against any antigen/

immunogen. In addition, the present invention provides means to create proteins with reduced immunogenicity for use in various applications.

[0010] The present invention was developed in order to avoid the issues arising from immunogenicity analyses in animals other than humans. However, it is not intended that the present invention be limited to use for human populations. Indeed, it is contemplated that the present invention will find use in other animal populations, in addition to humans, including but not limited to non-human primates. In preferred embodiments of the present invention, means are provided to rank the immunogenicity of proteins using human peripheral blood monocytes (PBMC) as the test "subject." Because large replicates of human samples are used, the information provided is applicable to general populations of humans. Importantly, the data do not suffer from the specificity issues surrounding the use of inbred mice. In preferred embodiments, the present invention provides means to rank proteins based on their overall immunogenicity. In addition, by comparing data with pre-existing animal data, the methods of the present invention provide information pertaining to the relative potency of proteins. For example, during the development of the present invention, four well-characterized industrial allergens were placed in the order determined by the GPIT and MINT tests, and were compared with the results obtained using the methods of the present invention, including determining the sensitization of occupationally exposed workers.

[0011] In preferred embodiments, the methods provided by the present invention involve the use of dendritic cells as antigen-presenting cells, 15-mer peptides offset by 3 amino acids that encompass an entire protein sequence of interest, and CD4⁺ T-cells obtained from the dendritic cell donors. T-cells are allowed to proliferate in a sample in the presence of the peptides (each peptide is tested individually) and differentiated dendritic cells. It is not intended that any of the methods of the present invention be conducted in any particular order, as far as preparation of pepsets and differentiation of dendritic cells. For example, in some embodiments, the pepsets are prepared before the dendritic cells are differentiated, while in other embodiments, the dendritic cells are differentiated before the pepsets are prepared, and in still other embodiments, the dendritic cells are differentiated and the pepsets are prepared concurrently. Thus, it is not intended that the present invention be limited to methods having these steps in any particular order.

[0012] If the proliferation in response to a peptide results in a stimulation index (SI) of at least 1.5, the response is considered and tallied as being "positive." The results for each peptide are tabulated for a donor set, which preferably reflects the general HLA allele frequencies of the population, albeit with some variation. The "structure value," based on the determination of difference from linearity is determined, and this value is used to rank the relative immunogenicity of the proteins. Thus, the present invention provides information useful in the modification of proteins, such that reduced response rates predicted to be effective in humans are achieved without the need to sensitize volunteers. Analyses of donor responses to peptide sets based on these new proteins that have been designed to be hypoimmunogenic are then conducted to calculate structure values for the new protein(s) and confirm their immunogenicity and exposure potentials.

[0013] In some preferred embodiments, the invention provides an assay system (i.e., the I-MUNE® assay) for ranking relative immunogenicity of proteins. In one embodiment, the

methods comprise measuring in vitro CD4⁺ T-cell proliferation in response to peptide fragments of a protein, compiling the measured responses for the protein, determining the structure value of the compiled responses, and comparing the structure value of the protein to the structure value of a second protein, wherein the protein comprising the lowest structure value is ranked as being less immunogenic to a human compared to a protein having a higher structure value. In alternative embodiments, the tested protein is an enzyme. In still further embodiments, the enzyme is a protease. In an additional embodiment, the tested protein is selected from the group consisting of antibodies, cytokines, soluble receptors, fusion proteins, structural proteins, binding proteins, and hormones. In a further embodiment, the T-cell proliferation of each peptide fragment and each protein is determined in side-by-side tests. In other embodiments, a "positive" response is determined based on an SI value between 2.7 and 3.2. In particularly preferred embodiments, the level of proliferation results in a stimulation index of 2.95 or greater.

[0014] The present invention also provides methods for assessing the reduced immunogenic capacity of variant proteins in humans. In some embodiments, the methods comprise reducing one or more prominent regions of a parent protein to a background level to create a variant protein, determining the structure value of the variant, and comparing the structure value of the variant with the structure value of the parent protein, wherein the lower structure value indicates a protein with reduced immunogenicity. In some preferred embodiments, the protein is an enzyme. In some alternative embodiments, the protein is selected from the group consisting of proteases, cytokines, soluble receptors, fusion proteins, structural proteins, binding proteins, hormones, antibodies, amylases, and other enzymes, including but not limited to subtilisins, ALCALASE[®] enzyme, cellulases, lipases, oxidases, isomerases, kinases, phosphatases, lactamases, and reductases. In further embodiments, the number of prominent regions reduced to background level are between 1 and 10, preferably between 1 and 5. In yet another embodiment, one or more amino acid residues are altered in the prominent region of the parent protein to create a variant.

[0015] The present invention also provides methods for selecting the least immunogenic protein from a group of related proteins. In one embodiment, the related proteins are antibodies, while in an alternative embodiment they are cytokines, and in yet another embodiment, they are hormones, and in still further embodiments they are soluble receptors, and in additional embodiments, they are fusion proteins. In a further embodiment, the related proteins are structural proteins, while in still further embodiments, they are binding proteins. In yet another embodiment, the proteins are enzymes. In some preferred embodiments, the enzymes are selected from the group consisting of proteases, cellulases, lipases, amylases, oxidases, isomerases, kinases, phosphatases, lactamases, and reductases.

[0016] The present invention further provides methods of using the relative ranking of related proteins to determine T-cell epitope modification suitable to reduce the immunogenicity of the proteins, particularly in humans. The present invention also provides means to categorize proteins based on both their background percent response and their structure values. Thus, in some further embodiments, the proteins analyzed are categorized and/or ranked according to their background percent response and structure values.

[0017] In some embodiments, the present invention provides methods for ranking the relative immunogenicity of a first protein and at least one additional protein, comprising the steps of: (a) preparing a first pepset from a first protein and preparing at least one additional pepset from each of the additional proteins; (b) obtaining a solution of dendritic cells and a solution of naïve CD4⁺ and/or CD8⁺ T-cells from at least one human blood source; (c) differentiating the dendritic cells to produce a solution of differentiated dendritic cells; (d) combining the solution of differentiated dendritic cells and the naïve CD4⁺ and/or CD8⁺ T-cells with the first pepset; (e) combining the solution of differentiated dendritic cells and the naïve CD4⁺ and/or CD8⁺ T-cells with each of the pepsets from the additional proteins; (f) measuring proliferation of the T-cells in steps (c) and (d); (g) determining the responses to each peptide in the first and additional pepsets; (h) compiling the responses of the T-cells in step (g) for the first protein and the additional proteins; (i) determining the structure value of the compiled responses of step (g) for the first protein and the additional proteins; and (j) comparing the structure value obtained for the first protein with the structure value for the additional proteins to determine the immunogenicity ranking of the first protein and the additional proteins. In some preferred embodiments, the pepsets comprise peptides of about 15 amino acids in length, while in some particularly preferred embodiments each peptide overlaps adjacent peptides by about 3 amino acids. However, it is not intended that the peptides within the pepsets be limited to any particular length nor overlap, as other peptide lengths and overlap amounts find use in the present invention.

[0018] In some embodiments, the protein having the lowest structure value is ranked as being less immunogenic than the protein having the higher structure value. In additional embodiments, the at least two proteins are selected from the group consisting of enzymes, hormones, cytokines, soluble receptors, fusion proteins, antibodies, structural proteins, and binding proteins. In still further embodiments, a positive response against the first protein comprises a stimulation index value between about 2.7 and about 3.2. In yet other embodiments, a positive response against the additional proteins comprises a stimulation index value between about 2.7 and about 3.2. In further embodiments, a positive response against the first protein comprises a stimulation index value between about 2.7 and about 3.2 and a positive response against the additional proteins comprises a stimulation index value between about 2.7 and about 3.2. In some embodiments, proliferation of the T-cells in steps (d) results in a stimulation index of about 2.95 or greater, while in additional embodiments, the proliferation of the T-cells in steps (e) results in a stimulation index of about 2.95 or greater. In still further embodiments, the proliferation of the T-cells in steps (d) results in a stimulation index of about 2.95 or greater and the proliferation of the T-cells in steps (e) results in a stimulation index of about 2.95 or greater. In some particularly preferred embodiments, at least one additional human blood source is used in step (b). In some additional particularly preferred embodiments, the structure values obtained for each of the human blood sources and the proteins are compared. The present invention also provides means to categorize proteins based on both their background percent response and their structure values. Thus, in some further embodiments, the proteins analyzed are categorized and/or ranked according to their background percent response and structure values.

[0019] The present invention also provides methods for ranking the relative immunogenicity of two proteins, wherein the second protein is a protein variant of the first protein, comprising the steps of: (a) preparing a first pepset from a first protein and a second pepset from a second protein; (b) obtaining from a single human blood source a solution comprising dendritic cells and a solution of naïve CD4+ and/or CD8+ T-cells; (c) differentiating the dendritic cells to produce a solution of differentiated dendritic cells; (d) combining the solution of differentiated dendritic cells and the naïve CD4+ and/or CD8+ T-cells with the first pepset; (e) combining the solution of differentiated dendritic cells and the naïve CD4+ and/or CD8+ T-cells with the second pepset; (f) measuring proliferation of the T-cells in steps (d) and (e), to determine the responses to each peptide in the first and second pepsets; (g) compiling the responses of the T-cells in step (f) for the first protein and the second protein; (h) determining the structure value of the compiled responses of step (g) for the first protein and the second protein; (i) comparing the structure value obtained for the first protein with the structure value for the second protein to determine the immunogenicity ranking of the first protein and the second protein. In some embodiments, the second protein is ranked as less immunogenic than the first protein, while in alternative embodiments, the first protein is ranked as less immunogenic than the second protein. In some preferred embodiments, the pepsets comprise peptides of about 15 amino acids in length, while in some particularly preferred embodiments each peptide overlaps adjacent peptides by about 3 amino acids. However, it is not intended that the peptides within the pepsets be limited to any particular length nor overlap, as other peptide lengths and overlap amounts find use in the present invention. In additional embodiments, the first and second proteins are selected from the group consisting of enzymes, hormones, cytokines, soluble receptors, fusion proteins, fusion proteins, soluble receptors, antibodies, structural proteins, and binding proteins. In still further embodiments, a positive response against the first protein comprises a stimulation index value between about 2.7 and about 3.2, while in other embodiments, a positive response against the second protein comprises a stimulation index value between about 2.7 and about 3.2. In additional embodiments, a positive response against the first protein comprises a stimulation index value between about 2.7 and about 3.2 and a positive response against the second protein comprises a stimulation index value between about 2.7 and about 3.2. In still further embodiments, the proliferation of the T-cells in steps (d) results in a stimulation index of about 2.95 or greater and the proliferation of the T-cells in steps (e) results in a stimulation index of about 2.95 or greater. In some particularly preferred embodiments, at least one additional human blood source is used in step (b). In some additional particularly preferred embodiments, the structure values obtained for each of the human blood sources and the proteins are compared. In some embodiments, the second protein comprises a reduction of at least one prominent region in the first protein. In further embodiments, the proliferation of the T-cells in step (e) is at a background level. In some particularly preferred embodiments, the structure values obtained for each of the human blood sources and the proteins are compared. The present invention also provides means to categorize proteins based on both their background percent response and their structure values. Thus, in some further

embodiments, the proteins analyzed are categorized and/or ranked according to their background percent response and structure values.

[0020] The present invention also provides methods for ranking the relative immunogenicity of a first protein and at least one variant protein, comprising the steps of: (a) preparing a first pepset from a first protein and pepsets from each of the variant proteins; (b) obtaining from a single human blood source a solution comprising dendritic cells and a solution of naïve CD4+ and/or CD8+ T-cells; (c) differentiating the dendritic cells to produce a solution of differentiated dendritic cells; (d) combining the solution of differentiated dendritic cells and the naïve CD4+ and/or CD8+ T-cells with the first pepset; (e) combining the solution of differentiated dendritic cells and the naïve CD4+ and/or CD8+ T-cells with each pepset prepared from each of the variant proteins; (f) measuring proliferation of the T-cells in steps (d) and (e), to determine the responses to each peptide in the first and second pepsets; (g) compiling the responses of the T-cells in step (f) for the first protein and the variant protein(s); (h) determining the structure value of the compiled responses of step (g) for the first protein and the variant protein(s); and (i) comparing the structure value obtained for the first protein with the structure value for the variant protein(s) to determine the immunogenicity ranking of the first protein and the variant proteins. In some preferred embodiments, the pepsets comprise peptides of about 15 amino acids in length, while in some particularly preferred embodiments each peptide overlaps adjacent peptides by about 3 amino acids. However, it is not intended that the peptides within the pepsets be limited to any particular length nor overlap, as other peptide lengths and overlap amounts find use in the present invention. In some preferred embodiments, at least one of the variant proteins is ranked as less immunogenic than the first protein, while in other embodiments, the first protein is ranked as less immunogenic than at least one of the variant proteins. In additional embodiments, first and the variant proteins are selected from the group consisting of enzymes, hormones, cytokines, soluble receptors, fusion proteins, antibodies, structural proteins, and binding proteins. In further embodiments, a positive response against the first protein comprises a stimulation index value between about 2.7 and about 3.2, while in other embodiments, a positive response against a variant protein comprises a stimulation index value between about 2.7 and about 3.2. In additional embodiments, a positive response against the first protein comprises a stimulation index value between about 2.7 and about 3.2 and a positive response against a variant protein comprises a stimulation index value between about 2.7 and about 3.2. In still further embodiments, the proliferation of the T-cells in steps (d) results in a stimulation index of about 2.95 or greater and the proliferation of the T-cells in steps (e) results in a stimulation index of about 2.95 or greater. In some particularly preferred embodiments, at least one additional human blood source is used in step (b). In some additional particularly preferred embodiments, the structure values obtained for each of the human blood sources and the proteins are compared. In some embodiments, the variant protein comprises a reduction of at least one prominent region in the first protein. In further embodiments, the proliferation of the T-cells in step (e) is at a background level. In some preferred embodiments, the proliferation of the T-cells in step (e) for at least one variant protein is at a background level. In some particularly preferred embodiments, the structure values obtained for each of

the human blood sources and the proteins are compared. In further embodiments, at least one additional human blood source is used in step (b). The present invention also provides means to categorize proteins based on both their background percent response and their structure values. Thus, in some further embodiments, the proteins analyzed are categorized and/or ranked according to their background percent response and structure values.

[0021] The present invention further provides methods for determining the immune response of a test population against a test protein, comprising the steps of: (a) preparing a pepset from a test protein; (b) obtaining a plurality of solutions comprising human dendritic cells and a plurality of solutions of naïve human CD4+ and/or CD8+ T-cells, wherein the solutions of human dendritic cells and solutions of naïve human CD4+ and/or CD8+ T-cells are obtained from a plurality of individuals within the test population; (c) differentiating the dendritic cells to produce a plurality of solutions comprising differentiated dendritic cells; (d) combining the plurality of the solutions of differentiated dendritic cells and the solutions of naïve CD4+ and/or CD8+ T-cells with the pepset, wherein each of the solutions of differentiated dendritic cells and the solutions of naïve CD4+ and/or CD8+ T-cells are from one individual within the test population are combined; (e) measuring proliferation of the T-cells in step (d), to determine the responses to each peptide in the pepset; (g) compiling the responses of the T-cells in step (e) for the test protein; (h) determining the structure value of the compiled responses of step (g) for the test protein; and (i) determining the level of exposure of the plurality of individuals to the test protein. In some preferred embodiments, the pepsets comprise peptides of about 15 amino acids in length, while in some particularly preferred embodiments each peptide overlaps adjacent peptides by about 3 amino acids. However, it is not intended that the peptides within the pepsets be limited to any particular length nor overlap, as other peptide lengths and overlap amounts find use in the present invention. In some embodiments, at least two test proteins are tested. In some preferred embodiments, the level of exposure of the plurality of individuals to the test protein is compared. In some particularly preferred embodiments, the test protein is modified to produce a variant protein that exhibits a reduced immunogenic response in the test population. The present invention also provides means to categorize proteins based on both their background percent response and their structure values. Thus, in some further embodiments, the proteins analyzed are categorized and/or ranked according to their background percent response and structure values.

[0022] In additional embodiments, a validation assay comprising a peripheral blood mononuclear cell response assessment is used to validate changes in proteins and/or epitopes based on the I-MUNE® assay system described herein. In particularly preferred embodiments, the "PBMC" assay is used as the validation assay. In additional embodiments, the PBMC assay is used as a predictor to determine which epitopes are suitable for amino acid alterations. Thus, the present invention finds use either as a two assay method for determining suitable alterations in proteins and/or epitopes to modify the immunogenicity of proteins, as well as means to predict amino acid sites that will modify the immunogenicity of proteins.

BRIEF DESCRIPTION OF THE FIGURES

[0023] FIG. 1 illustrates the average frequency of the HLA-DRB1 allele for 184 random individuals in the community donor population compared to published "Caucasian" HLA-DRB1 populations.

[0024] FIG. 2 illustrates the percent of responders from a population of 82 random individuals tested with peptides derived from *Bacillus licheniformis* alpha amylase. The consecutive 15-mer peptides offset by 3 amino acids are listed on the x-axis and the percentages of donors who responded to each peptide are shown on the y-axis.

[0025] FIG. 3 illustrates the percent of responders from a population of 65 random individuals tested with peptides derived from *Bacillus lentus* subtilisin. The consecutive 15-mer peptides offset by 3 amino acids are listed on the x-axis and the percent of donors who responded to each peptide is shown on the y-axis.

[0026] FIG. 4 illustrates the percent responders from a population of 113 individuals tested with two peptide sets from a *Bacillus* BPN' subtilisin Y217L. The consecutive 15-mer peptides offset by 3 amino acids are listed on the x-axis and the percentage of donors who responded to each peptide are shown on the y-axis.

[0027] FIG. 5 illustrates the percent responders from a population of 92 individuals tested with peptides derived from ALCALASE® enzyme. The consecutive 15-mer peptides offset by 3 amino acids are listed on the x-axis and the percentages of donors who responded to each peptide are shown on the y-axis.

[0028] FIG. 6 provides a graph showing that the calculated structure values decrease with increasing number of responses per peptide. The structure values shown were those determined for α -amylase (squares) and BPN' Y217L (diamonds), as responses accumulated.

[0029] FIG. 7, Panels A and B provide a comparison between GPIT (Panel A) and MINT (Panel B) ranking data and the structure index values for four industrial enzymes. The relative allergenicities of α -amylase, ALCALASE® enzyme, BPN' Y217L, and *B. lentus* subtilisin as determined in guinea pig (GPIT) and mouse (MINT)-based assays are compared to the structure index values (y-axis).

[0030] FIG. 8 provides a graph showing a limited dataset indicating the variant peptide responses used to calculate the structure for the BPN' Y217L variant. Forty-eight community donors were tested with peptides derived from the sequence of BPN' Y217L. The consecutive 15-mer peptides offset by 3 amino acids are listed on the x-axis and the percentages of the donors who responded to each peptide are shown on the y-axis. The last two peptides represent variant sequences of peptides number 24 and 37.

[0031] FIG. 9 provides a graph showing the maximum proliferative responses of PBMC from 30 community donors to BPN' Y217L (open triangles, structure value=0.53) and the unmodified BPN' Y217L variant (closed squares, structure value=0.40). Each donor's maximum response is shown on the y-axis. An SI of 2.0 was the cut-off for a "positive" response. The difference in proliferative responses between BPN' Y217L and the variant was $p < 0.01$.

[0032] FIG. 10 provides a graph showing the average percent response per peptide for each of 11 tested proteins for the donors tested.

[0033] FIG. 11 provides a graph showing the frequency of responses to *B. lentus* subtilisin ($n=65$ community donors). This Figure shows the percent of responses to linear peptides describing the sequence of subtilisin. The consecutive peptides are shown on the x-axis. Percent response within the 65 donors is on the y-axis.

[0034] FIG. 12 provides a graph showing the frequency of responses within the set. The frequency of responses to the peptides within the *B. lentus* peptide set is shown.

[0035] FIG. 13 provides a graph showing the responses of seven SPT+ (skin prick test positive) donors to *B. lentus* peptides. PBMC from 7 donors verified to be sensitized to *B. lentus* subtilisin by skin prick test were used in the I-MUNE® assay of the present invention to test for their responses to *B. lentus* subtilisin peptides. A response to a peptide was considered positive if an SI of 2.95 or greater was observed. The number of donors responding to each peptide is shown on the y-axis. The consecutive *B. lentus* peptides are shown on the x-axis.

[0036] FIG. 14 provides graphs showing I-MUNE® assay data results for staphylokinase.

[0037] Panel A provides the percent responders per peptide (n=72). The consecutive staphylokinase peptides are shown on the x-axis. The percent responders within the donor set of 72 is shown on the y-axis. Panel shows the frequency of responses per peptide.

[0038] FIG. 15 provide a table showing the epitope alignment between the I-MUNE® assay is results obtained using the I-MUNE® assay system of the present invention and published epitopes for staphylokinase.

[0039] FIG. 16 provides graphs showing the I-MUNE® assay results for β 2-microglobulin.

[0040] Panel A shows the percent responders per peptide (n=87). The consecutive human β 2-microglobulin peptides are shown on the x-axis. The percent response within the 87 donor set 20 is shown on the y-axis. Panel B shows the frequency of responses per peptide.

[0041] FIG. 17 provides a table showing the IC₅₀ binding values for epitope peptides identified in bacterial proteases by the I-MUNE® assay system of the present invention.

[0042] Values less than 500 nM are considered to be good binders and are highlighted in bold in the Table. Degeneracy indicates the number of HLA class II proteins that bind with an IC₅₀ of less than 500 nM out of the 18 total alleles tested.

[0043] FIG. 18 provides a table showing the responses of 69 community donors to a peptide set describing the amino acid sequence of beta-lactamase.

[0044] FIG. 19 provides a graph showing the responses to peptide #6 (SEQ ID NO:2) and two variants (SEQ ID NOS:10 and 11).

[0045] FIG. 20 provides a graph showing the responses to peptide #36 (SEQ ID NO:3) and three variants (SEQ ID NOS:20, 21, and 25).

[0046] FIG. 21 provides a graph showing the responses to peptide #49 (SEQ ID NO:4) and one variant (SEQ ID NO:40).

[0047] FIG. 22 provides a graph showing the responses to peptide #107, and five variants (SEQ ID NOS: 48, 49, 50, 52, and 53).

[0048] FIG. 23 provides a graph showing the responses to peptide #49 and a series of modified epitopes.

[0049] FIG. 24 provides a graph showing the responses to peptide #49 with the substitution 1155SF (SEQ ID NO:59) and a pepset based on this sequence.

[0050] FIG. 25 provides a graph showing the responses to peptide #49 with the substitution 1155V (SEQ ID NO:63) and a pepset based on this sequence.

[0051] FIG. 26 provides a graph showing the responses to peptide #49 with the substitution 1155L (SEQ ID NO:69) and a pepset based on this sequence.

[0052] FIG. 27 provides a graph showing the responses to peptide #49 with the substitution T147Q (SEQ ID NO:75) and a pepset based on this sequence.

[0053] FIG. 28 provides a graph showing the responses to peptide #49 with the substitution-L149S (SEQ ID NO:82) and a pepset based on this sequence.

[0054] FIG. 29 provides a graph showing the responses to peptide #49 with the substitution L149R (SEQ ID NO:87) and a pepset based on this sequence.

[0055] FIG. 30 provides graphs showing the results from the PBMC assay used to test beta-lactamase (SEQ ID NO:1) and two epitope-modified beta-lactamases. Panel A is a graph showing the average proliferative responses obtained for each enzyme, while Panel B is a graph showing the percent of responders for each enzyme.

[0056] FIG. 31 provides graphs showing the PBMC assay results for BPN^o Y217L (Panel A), and BLA (Panel B).

[0057] FIG. 32 provides a graph showing the SI for parent molecules and modified variants.

[0058] FIG. 33 provides a graph showing that modification of immunodominant CD4+ T-cell epitopes results in a sharp reduction in both the frequency and magnitude of responses.

[0059] FIG. 34 provides a graph showing the SI for various food extracts.

DESCRIPTION OF THE INVENTION

[0060] The present invention provides means to assess immune response profiles of populations. In particular, the present invention provides means to qualitatively assess the immune response of human populations, wherein the immune response directed against any protein of interest is analyzed. The present invention further provides means to rank proteins based on their relative immunogenicity. In further embodiments, the present invention provides means for verifying immunological response data, as well as means for predicting immune responses directed against any antigen/immunogen. In addition, the present invention provides means to create proteins with reduced immunogenicity for use in various applications.

[0061] The present invention provides ex vivo techniques for the identification of CD4+ T-cell epitopes on a human population basis. Within a donor population pre-sensitized to the protein of interest, all recall epitopes can be defined. For a donor population defined as un-sensitized to the protein of interest, either primary or cross-reactive epitopes are identified. While the latter cannot be formally ruled out, a number of points support the conclusion that the epitopes found are primary epitopes. First, the epitopes found in industrial proteins are largely promiscuous binders with low IC₅₀ values in an in vitro binding assay. Recall responses are marked by lower threshold values over time rather than being narrowed to the highest binding values (See, Hesse et al., *J. Immunol.*, 167:1353-1361 [2001]). Second, a subset of total recall epitopes is always found when using presumably un-sensitized donors. This is a characteristic of primary, immunodominant epitopes (See, Muraro et al., *J. Immunol.*, 164: 5474-5481[2000]; Vanderlugt, *Nat. Rev. Immunol.*, 2:85-95 [2002]; Vanderlugt, *J. Immunol.*, 164:670-678 [2000]; and Yin et al., *J. Immunol.*, 26:2063-2068 [1998]). Third, β -2 microglobulin was tested as a set of 15-mer peptides off-set by 3 amino acids, representing a group of 52 peptides to which no prominent epitope responses were found. It seems unlikely that none of these sequences would be found to be cross-reactive sequences in any other proteins. Four, when a

epitope cross-reactive with a sequence found in a protein from a human pathogenic agent is found, as was the case for one bacterial enzyme protein examined, the percent responses to the epitope peptide were very high (30%), much higher than any responses collated in the other 10 industrial enzymes tested as described in Example 7 (data not shown). Five, the I-MUNE® assay system of the present invention is performed using CD4+ T cell enriched responders cells and activated monocyte-derived dendritic cells as APCs. The magnitude of proliferative responses seen is very small, consistent with a low precursor frequency of antigen-specific CD4+ T cells. Recall proliferative responses were detected as being much more robust than the responses detected in the presumably un-sensitized population. Finally, BLAST searches were performed with the epitope sequences. For the *Bacillus*-derived proteins, *Bacillus* species contain protease variants that have modifications within the epitope sequences identified. However, it is unlikely that the donor pool would become sensitized to these, or any of the other *Bacillus serine* proteases (with the notable cross-reactive example cited above). Interestingly, there is some homology (66% homology) of the amino acids 70-84 epitope region in BPN^Y217L to a region in a putative human-derived ATP-dependent RNA helicase (See, Imamura et al., Nucl. Acids Res., 26:2063-2068 [1998]). Homology to a widely expressed housekeeping gene such as this might be expected to induce tolerance rather than provoke a cross-reactive response.

[0062] The background rate is an important consideration in analyzing population data. The background rate is contributed to by both accumulating positive responses at epitope peptides, as well as random events that reach the 2.95 SI cut-off value. The low level of randomly accumulating positive responses reflects the heterogeneity of the proliferation status of CD4+ T cells in human donors (See, Asquith et al., Trends Immunol., 23:595-601 [2002]). While the background could be reduced artificially by raising the cut-off response value, having a measurable rate of background allows for the determination of where the frequency of responses accumulate in a non-random manner. In spite of all the variables included in the I-MUNE® assay system, the coefficient of variance (CV) for the frequency of epitope responses was very good (an average of 20% for four tested peptides). This level of reproducibility compares favorably to coefficient of variable values reported for intra-laboratory and inter-donor repeat testing of primary ELISPOT data, an analogous ex vivo assay (Keilhoz et al., J. Immunother., 25:97-138 [2002]; and Asai et al., Clin. Diag. Lab Immunol., 7:145-154 [2000]). Generally, CV values decline as the percent response to an epitope peptide increases. In addition, non-epitope peptide responses with reduced frequencies (usually less than 10% of the donor population) have increased CV values. For example, in Example 7, the overall background rate was 3.15% with a standard deviation of 1.6%, a CV of 51%.

[0063] The statistical method for defining epitope peptides is different if the population demonstrates presensitization to the protein of interest. An increased background response is likely due to the reduced threshold for functional activation seen in recall responses (See, Hesse et al., supra). Reduced thresholds for functional activation result in more epitopes being detected by the I-MUNE® assay system of the present invention. A comparison of the I-MUNE® assay system results with data from sensitized donors showed that the prominent epitope responses in the I-MUNE® assay data

aligned with epitope responses defined by clonal CD4+ T cell lines. By reducing the level of stringency of the statistical method, the selection of epitope peptides within the I-MUNE® assay system corresponded with the published epitope sequences. The designation of epitope status in datasets with very low background rates, such as the industrial enzyme data, was more stringent. When the background responses are very low, many peptides accumulate responses that meet the cut-off value if the reduced stringency determination is used, but the overall frequency of responses is very low, and will be difficult to reproduce. Typically, when responses are less than 10% of the total population they become difficult to reproduce due to the technical difficulty of testing more than 100 donors. Significant epitope responses are easily deduced from the frequency data, where epitope responses are outliers. Epitope peptide sequences in un-sensitized donors likely reflect tight binding promiscuous epitopes capable of inducing de-novo proliferation (Viola and Lanzavecchia, Science 273:104-106 [1996]; and Rachmilewitz and Lanzavecchia, Trends Immunol., 23:592-595 [2002]). This was confirmed for epitope peptides designated in two industrial enzymes by in vitro peptide binding studies (See, Example 7).

[0064] The I-MUNE® assay system of the present invention did not identify any epitopes in human β 2-microglobulin. This result highlights the difference between the I-MUNE® assay system of the present invention and algorithm-based HLA class II binding prediction methods. Peptide-binding algorithms freely available via the internet and known to those in the art, predict class II binding epitopes in this sequence. However, as exemplified by the results presented here, binding to a class II molecule does not always indicate the presence of a functional epitope. Binding to HLA class II is necessary, but not sufficient, to define T cell epitopes. This is a well-known property of predictive methods, and therefore these methods are often supplemented with functional testing. However, the present invention provides a more direct means to obtain this information.

[0065] It is important to note that the epitope determinations described herein are defined on a population basis. While prominent epitopes often show some level of HLA specificity, the epitope peptides are largely defined by their promiscuous HLA binding capacity. Because of this, these epitopes are likely supertype binders and therefore represent good candidates for modification, if a hypo-immunogenic protein is sought. However, it is contemplated that due to the population based analysis, hypo-immunogenic proteins created using these results as a guide are not always non-immunogenic in every discrete instance. Nonetheless, defining T-cell epitopes on a population basis finds use in characterization of immune responses to infectious agents (See, Novitsky et al., J. Virol., 76:10155-10168 [2002]; and Pathan et al., J. Immunol., 167:5217-5225 [2001]). One purpose for such studies is to design efficacious vaccines, where the inclusion of promiscuous supertype binders is also warranted. Interestingly, when the data presented in one of these studies (Pathan et al., supra) was subjected to analysis by the exposed-donor method defined herein, the same set of dominant epitope responses were selected (data not shown).

[0066] In addition to its utility in the infectious disease setting, as well as protein analyses, the methods of the present invention provide means to localize the functional CD4+ T cell epitopes in any protein of interest. When the donor population is expected to be un-exposed to the protein of interest,

the background response rate is low, and stringent statistics can be applied to the selection of CD4+ epitope sequences. Interestingly, human proteins have very low background responses. A high background level corresponds with donor exposure to the protein of interest, and the epitope determination relies on less stringent criteria. Epitope designations have been validated by comparison to results for verified sensitized donors. As indicated above, no epitopes were found in human β -2 microglobulin, as would be expected for a ubiquitously expressed protein that imprints tolerance on the immune system. Thus, the present I-MUNE® assay system provides a valuable tool for predicting population-based CD4+ T-cell epitopes. The applications for this technology include the creation of hypo-immunogenic protein variants, the selection of epitope regions for the creation of epitope-based vaccines, and as a tool for inclusion in the risk assessment evaluation of all commercial proteins.

[0067] Indeed, the present invention provides means to reduce the sensitization potential of CD4+ T-cells. This is particularly of use in target populations that have not been previously exposed to a potential commercial protein or any other protein intended for use by/for humans and other animals. Indeed, in addition to the creation of hypo-allergenic/immunogenic commercial protein variants, T-cell epitope identification is the basis of many vaccine strategies (Alexander et al., *Immunol. Res.*, 18:79-2 [1998]; and Berzofsky, *Ann. N.Y. Acad. Sci.*, 690:256-264 [1993]). The identification of T cell epitopes recognized by individuals who clear pathogens versus those who do not is of interest to the design of both cancer and viral vaccines (Manici et al., *J. Exp. Med.*, 189:871-87 [1999]; Doolan et al., *J. Immunol.*, 165:1123-1137; and Novitsky et al., *J. Virol.*, 76:10155-10168 [2002]). The utility of hypo-allergenic/immunogenic proteins is also clear for personal care, health care, and home care settings, as well as in commercial applications. Indeed, such hypo-allergenic/immunogenic proteins find use in innumerable settings and uses.

[0068] For the creation of CD4+ T cell epitope-modified proteins, the first critical step is the localization of functional epitopes within the protein. There are a number of computer-based methods for predicting the localization of peptide sequences that bind to HLA class II molecules (Yu et al., *Mol. Med.*, 8:137-148 [2002]; Rammensee et al., *Immunogenet.*, 50:213-219 [1990]; Stumliolo et al., *Nat. Biotechnol.*, 17:555-561 [1999]; and Altuvia et al., *J. Mol. Biol.*, 249:244-250 [1995]). Binding to HLA is necessary, but not sufficient, for CD4+ T cell activation. Optimally, in vitro and in vivo testing must be performed to confirm functionality. Computer based methods are improving in their ability to correctly identify tight HLA binders, but still suffer from a lack of prediction for binding non HLA-DR class II molecules, and a significant false negative rate. In addition, functional differences such as the induction of tolerance, and epitopes that induce differential responses by activated T cells cannot be assessed using computer modeling.

[0069] Thus, the present invention provides means heretofore unavailable for the identification and confirmation of functionality of methods for assessing CD4+ T-cell epitope-modified proteins. In some embodiments, the present invention provides in vitro human cell based method for the localization of immunodominant, promiscuous HLA class II epitopes from any protein of interest. The method applies equally well to industrial enzymes, food allergens, and human therapeutic proteins as it does to the delineation of

population-based epitope responses to pathogen-derived proteins, as well as any other protein of interest. In preferred embodiments, large donor sets are tested without pre-selection for HLA type. Epitope determinations are made based on statistical analyses of the response rates by the entire donor set to all the peptides derived from the sequence of the protein, and therefore represent population-based epitopes. As indicated herein, the methods of the present invention are capable of distinguishing between proteins to which the donor population has been exposed, from proteins that the donor population has not previously encountered or has not become sensitized to. During the development of the present invention, both types of analyses were compared to proliferation results from verified antigen-sensitized donors. In addition, human β 2-microglobulin was tested and confirmed as a negative control.

[0070] As referred to herein, epitope peptides are designated by difference from the background response rate. Epitope peptide responses are reproducible, with a median coefficient of variance of 21% when tested on multiple random-donor sets. In addition, as discussed in greater detail herein, the I-MUNE® assay system of the present invention identified recall epitopes for the protein staphylokinase, and identified immunodominant promiscuous epitopes in industrial proteases representing a subset of the total recall epitopes. Furthermore, the I-MUNE® assay system found no epitopes in the negative control (i.e., human β -2 microglobulin). Importantly, the present invention provides means to identify functional CD4+ T cell epitopes in any protein without pre-selection for HLA class II type, suggesting whether a donor population is pre-exposed to a protein of interest, and does not require sensitized donors for in vitro testing.

[0071] During the development of the present invention, the use of statistical analysis of peptide-specific responses in a large human donor pool provided a metric that ranked four industrial enzymes in the order determined by both mouse and guinea pig exposure models. The ranking method also compared favorably to human sensitization rates in occupationally exposed workers. Additional confirmation of the methods of the present invention were also determined, based on structure values for proteins known to cause sensitization in humans. Comparison of these results indicated that the sensitization levels were found to be higher than the value determined for human β 2-microglobulin. In preferred embodiments, the present invention provides comparative methods to predict the immunogenicity of various related and unrelated proteins in humans. Thus, the information provided by the present invention finds use in the early development of protein therapies and other protein-based applications to select or create reduced immunogenicity variants.

[0072] Further during the development of the present invention, methods were developed to validate in vitro changes to proteins that were guided by the I-MUNE® assay. This additional assay system (the "PBMC" assay) utilizes whole protein molecules and unfractionated human peripheral blood mononuclear cells (PBMCs). In some embodiments, the control, unmodified parent proteins and variants developed using the I-MUNE® assay were parametrically tested in the PBMC assay. Reduction in the average SI and the percent response rates were analyzed. In tests used to validate the PBMC assay, control positive and negative proteins were tested, as described herein. The results indicated that the assay was capable of detecting potential antigenicity, pre-existing immunity and pre-existing tolerance induction. In

addition, the present PBMC assay provides means for the rapid screening of multiple-protein samples and very large proteins.

[0073] Although in vitro proliferative responses of community donor PBMCs to proteins have been described (See e.g., Young, *Immunol. Meth.*, [1995]; Plebanski, J. *Immunol. Meth.*, [1994]; and Ford, *Hum. Immunol.*, [1982]), predictive uses of such methods have not been described. In addition, the loss of reactivity to food allergens has been shown for two common food allergens by determining the percent response and average SI levels (See, Sopo, PAI [1999]). Likewise, although proliferative responses to food allergens have been shown to correlate with future development of allergy (Kobayashi, *JACI* [1994]), there remains a need to predict food allergenicity. As indicated above, predictive methods for allergenicity determinations largely rely on animal models (See, Helm, COACI [2002]) or computer-based sequence alignment methods (See, Stadler, FASEB [2003]). Furthermore, other than the methods described herein, predictive methods for immunogenicity testing are also largely computer algorithm based (See, DeGroot, *Dev. Biol.*, [2003]).

[0074] As described in greater detail herein, the PBMC assay of the present invention involves selection of an appropriate concentration for testing proteins as a preliminary step. Furthermore, in particularly preferred embodiments, the protein solutions are endotoxin free. In preferred embodiments, cells obtained from community donors are parametrically tested with the “parent” and modified proteins and/or with a set of protein variants. These methods facilitate determination of the relative immunogenicity of the proteins. In addition, the present invention provides means to verify the results obtained and epitope modifications indicated by the I-MUNE® assay system. These methods provide advantages over the currently used, yet usually unsuccessful systems of using humanized antibody sequences, human sequence-derived cytokines, and algorithm-based means for predicting and modifying T-cell epitopes.

DEFINITIONS

[0075] Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. For example, Singleton and Sainsbury, *Dictionary of Microbiology and Molecular Biology*, 2d Ed., John Wiley and Sons, NY (1994); and Hale and Marham, *The Harper Collins Dictionary of Biology*, Harper Perennial, N.Y. (1991) provide those of skill in the art with a general dictionaries of many of the terms used in herein. Although any methods and materials similar or equivalent to those described herein find use in the practice of the present invention, the preferred methods and materials are described herein. Accordingly, the terms defined immediately below are more fully described by reference to the Specification as a whole.

[0076] As used herein, the term “population” refers to the individuals associated with, and/or residing, in a given area. In some embodiments, the term is used in reference to a number of individuals that share a common characteristic (e.g., the population with a particular HLA type, etc.). Although the term is used in reference to human populations in preferred embodiments, it is not intended that the term be limited to humans, as it finds use in reference to other animals and organisms. In some embodiments, the term is used in

reference to the total set of items, characteristics, individuals, etc., from which a sample is taken.

[0077] As used herein, the term “population-based immune response” refers to the immune response profiles (i.e., characteristics) of the members of a population.

[0078] As used herein, the term “immune response” refers to the immunological response mounted by an organism (e.g., a human or other animal) against an immunogen. It is intended that the term encompass all types of immune responses, including but not limited to humoral (i.e., antibody-mediated), cellular, and non-specific immune responses. In some embodiments, the term reflects the immunity levels of populations (i.e., the number of people who are “immune” to a particular antigen and/or the number of people who are “not immune” to a particular antigen).

[0079] As used herein, the term “reduced immunogenicity” refers to a reduction in the immune response that is observed with variant (e.g., derivative) proteins, as compared to the original wild-type (e.g. parental or source) protein. In preferred embodiments of the present invention, variant proteins that stimulate a less robust immune response in vitro and/or in vivo, as compared to the source protein are provided. It is contemplated that these proteins having reduced immunogenicity will find use in various applications, including but not limited to bioproducts, protein therapeutics, food and feed, personal care, detergents, and other consumer-associated products, as well as in other treatment regimens, diagnostics, etc.

[0080] As used herein, the term “enhanced immunogenicity” refers to an increase in the immune response that is observed with variant (e.g., derivative) proteins, as compared to the original wild-type (e.g. parental or source) protein. In preferred embodiments of the present invention, variant proteins that stimulate a more robust immune response in vitro and/or in vivo, as compared to the source protein are provided. It is contemplated that these proteins having enhanced immunogenicity will find use in various applications, including but not limited to bioproducts, protein therapeutics, food and feed additives, as well as in other treatment regimens, diagnostics, etc.

[0081] As used herein, “allergenic food protein” refers to any food protein that is associated with causing an allergic reaction in humans and other animals. A “putative allergenic food protein” is a food protein that may be allergenic. A “food protein with reduced allergenicity” is a food protein that has been modified so as to be less allergenic (i.e., “hypoallergenic”) than the original, unmodified protein. It is intended that these terms encompass naturally-occurring food proteins, as well as those produced synthetically and/or using recombinant technology.

[0082] As used herein “altered immunogenic response,” refers to an increased or reduced immunogenic response. Proteins and peptides exhibit an “increased immunogenic response” when the T-cell and/or B-cell response they evoke is greater than that evoked by a parental (e.g., precursor) protein or peptide (e.g., the protein of interest). The net result of this higher response is an increased antibody response directed against the variant protein or peptide. Proteins and peptides exhibit a “reduced immunogenic response” when the T-cell and/or B-cell response they evoke is less than that evoked by a parental (e.g., precursor) protein or peptide. The net result of this lower response is a reduced antibody

response directed against the variant protein or peptide. In some preferred embodiments, the parental protein is a wild-type protein or peptide.

[0083] As used herein, “Stimulation Index” (SI) refers to a measure of the T-cell proliferative response of a peptide compared to a control. The SI is calculated by dividing the average CPM (counts per minute) obtained in testing the CD4+ T-cell and dendritic cell culture containing a peptide by the average CPM of the control culture containing dendritic cells and CD4+ T-cells but without the peptides. This value is calculated for each donor and for each peptide. While in some embodiments, SI values greater than about are used to indicate a positive response, in some embodiments, SI values of between about 1.5 to 4.5 are used to indicate a positive response, and the preferred SI value to indicate a positive response is between 2.5 and 3.5, inclusive, preferably between 2.7 and 3.2 inclusive, and more preferably between 2.9 and 3.1 inclusive. The most preferred embodiments described herein use a SI value of 2.95.

[0084] As used herein, the term “dataset” refers to compiled data for a set of peptides and a set of donors for tested for their responses against each test protein (i.e., a protein of interest).

[0085] As used herein, the term “pepset” refers to the set of peptides produced for each test protein (i.e., protein of interest). These peptides in the pepset (or “peptide sets”) are tested with cells from each donor.

[0086] As used herein, the terms “Structure” and “Structure Value” refer to a value to rank the relative immunogenicity of proteins. The structure value is determined according to the “total variation distance to the uniform” formula below:

$$\sum \left| f(i) - \frac{1}{p} \right|$$

wherein:

[0087] Σ (upper case sigma) is the sum of the absolute value of the frequency of responses to each peptide minus the frequency of that peptide in the set; $f(i)$ is defined as the frequency of responses for an individual peptide; and p is the number of peptides in the peptide set. In preferred embodiments of the present invention, a structure value is determined for each protein tested. Based on the structure values obtained, the test proteins are ranked from the lowest value to the highest value in the series of tested proteins. In this ranked series, the lowest value indicates the least immunogenic protein, while the highest value indicates the most immunogenic protein.

[0088] The structure value is dependent on the number of donors (i.e., the number of blood samples obtained from different individuals) tested. In general, zero responses across the entire dataset provide a structure value of 1.0. The same number of responses at each peptide returns a structure value of zero. Therefore, in preferred embodiments, a peptide set should be tested until there are responses across the majority of the dataset, in order for the data to accurately reflect responsively to particular peptides and peptide regions. In particularly preferred embodiments, there is a response to every peptide in the dataset. However, some datasets do not exhibit responses to every peptide in the dataset due to various factors (e.g., insolubility issues).

[0089] While the above formula is the preferred formula to use for determination of the structure value, other equivalent

formulas find use in the present invention. For example, the “entropy of the distribution” formula finds use in the present invention, as well as various other formulae known to those in the art.

[0090] In some embodiments, the peptide sets are tested with at least as many donors as should produce a response per peptide given the overall rate of 3% non-specific responses. For example, in preferred embodiments, a peptide set of 88 peptides is tested with a minimum of 30 donors. Thus, in embodiments in which the pepset includes more peptides, the number of donors is adjusted accordingly. Nonetheless, 30 donors is the preferred minimum number. Of course, more donors may be tested using the methods of the present invention, even when fewer peptides are present within a pepset. In some preferred embodiments, the dataset includes at least 50 donors, in order to provide good HLA allele representation.

[0091] As used herein, a “prominent response” refers to a peptide that produces an in vitro T-cell response rate in the dataset that is greater than about 2.0-fold the background response rate. In a further embodiment, the response is about a 2.0-fold to about a 5.0-fold increase above the background response rate. Also included within this term are responses that represent about a 2.5 to 3.5-fold increase, about a 2.8 to 3.2-fold increase, and a 2.9 to 3.1-fold increase above the background response rate. For example, during the development of the present invention, prominent responses were noted for some of the peptides.

[0092] As used herein, “prominent region” refers to an I-MUNE® assay response obtained with a particular peptide set that is greater than about 2.0-fold the background response rate. In one embodiment of the present invention, all of the prominent regions of a protein are reduced so that their responses in the I-MUNE® assay system of the present invention are reduced. In further embodiments, the number of prominent regions are reduced by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more, and preferably between 1 and 5 prominent regions are reduced in related proteins. In some embodiments, prominent regions also meet the requirements for a T-cell epitope.

[0093] The term “sample” as used herein is used in its broadest sense. However, in preferred embodiments, the term is used in reference to a sample (e.g., an aliquot) that comprises a peptide (e.g., a peptide within a pepset, that comprises a sequence of a protein of interest) that is being analyzed, identified, modified, and/or compared with other peptides. Thus, in most cases, this term is used in reference to material that includes a protein or peptide that is of interest.

[0094] As used herein, “background level” and “background response” refer to the average percent of responders to any given peptide in the dataset for any tested protein. This value is determined by averaging the percent responders for all peptides in the set, as compiled for all the tested donors. As an example, a 3% background response would indicate that on average there would be three positive (SI greater than 2.95) responses for any peptide in a dataset when tested on 100 donors.

[0095] As used herein, “antigen presenting cell” (“APC”) refers to a cell of the immune system that presents antigen on its surface, such that the antigen is recognizable by receptors on the surface of T-cells. Antigen presenting cells include, but are not limited to dendritic cells, interdigitating cells, activated B-cells and macrophages.

[0096] As used herein, the terms “T lymphocyte” and “T-cell,” encompass any cell within the T lymphocyte lineage from T-cell precursors (including Thy1 positive cells which

have not rearranged the T cell receptor genes) to mature T cells (i.e., single positive for either CD4 or CD8, surface TCR positive cells).

[0097] As used herein, the terms “B lymphocyte” and “B-cell” encompasses any cell within the B-cell lineage from B-cell precursors, such as pre-B-cells (B220⁺ cells which have begun to rearrange Ig heavy chain genes), to mature B-cells and plasma cells.

[0098] As used herein, “CD4⁺ T-cell” and “CD4 T-cell” refer to helper T-cells; while “CD8⁺ T-cell” and “CD8 T-cell” refer to cytotoxic T-cells.

[0099] As used herein, “B-cell proliferation,” refers to the number of B-cells produced during the incubation of B-cells with the antigen presenting cells, with or without the presence of antigen.

[0100] As used herein, “baseline B-cell proliferation,” as used herein, refers to the degree of B-cell proliferation that is normally seen in an individual in response to exposure to antigen presenting cells in the absence of peptide or protein antigen. For the purposes herein, the baseline B-cell proliferation level is determined on a per sample basis for each individual as the proliferation of B-cells in the absence of antigen.

[0101] As used herein, “B-cell epitope,” refers to a feature of a peptide or protein which is recognized by a B-cell receptor in the immunogenic response to the peptide comprising that antigen (i.e., the immunogen).

[0102] As used herein, “altered B-cell epitope,” refers to an epitope amino acid sequence which differs from the precursor peptide or peptide of interest, such that the variant peptide of interest produces different (i.e., altered) immunogenic responses in a human or another animal. It is contemplated that an altered immunogenic response encompasses altered immunogenicity and/or allergenicity (i.e., an either increased or decreased overall immunogenic response). In some embodiments, the altered B-cell epitope comprises substitution and/or deletion of an amino acid selected from those residues within the identified epitope. In alternative embodiments, the altered B-cell epitope comprises an addition of one or more residues within the epitope.

[0103] “T-cell proliferation,” as used herein, refers to the number of T-cells produced during the incubation of T-cells with the antigen presenting cells, with or without the presence of antigen.

[0104] “Baseline T-cell proliferation,” as used herein, refers to the degree of T-cell proliferation that is normally seen in an individual in response to exposure to antigen presenting cells in the absence of peptide or protein antigen. For the purposes herein, the baseline T-cell proliferation level is determined on a per sample basis for each individual as the proliferation of T-cells in response to antigen presenting cells in the absence of antigen.

[0105] As used herein, “T-cell epitope” refers to a feature of a peptide or protein which is recognized by a T-cell receptor in the initiation of an immunogenic response to the peptide comprising that antigen (i.e., the immunogen). Although it is not intended that the present invention be limited to any particular mechanism, it is generally believed that recognition of a T-cell epitope by a T-cell is via a mechanism wherein T-cells recognize peptide fragments of antigens which are bound to Class I or Class II MHC (i.e., HLA) molecules expressed on antigen-presenting cells (See e.g., Moeller, Immunol. Rev., 98:187 [1987]).

[0106] As used herein, “altered T-cell epitope,” refers to an epitope amino acid sequence which differs from the precursor peptide or peptide of interest, such that the variant peptide of interest produces different immunogenic responses in a human or another animal. It is contemplated that an altered immunogenic response encompasses altered immunogenicity and/or allergenicity (i.e., an either increased or decreased overall immunogenic response). In some embodiments, the altered T-cell epitope comprises substitution and/or deletion of an amino acid selected from those residues within the identified epitope. In alternative embodiments, the altered T-cell epitope comprises an addition of one or more residues within the epitope.

[0107] As used herein, “protein of interest,” refers to a protein (e.g., protease) which is being analyzed, identified and/or modified. Naturally-occurring, as well as recombinant proteins find use in the present invention. Indeed, the present invention finds use with any protein against which it is desired to characterize and/or modulate the immunogenic response of humans (or other animals). In some embodiments, proteins including hormones, cytokines, soluble receptors, fusion proteins, antibodies, enzymes, structural proteins and binding proteins find use in the present invention. In some embodiments, hormones, including but not limited to insulin, erythropoietin (EPO), thrombopoietin (TPO) and luteinizing hormone (LH) find use in the present invention. In further embodiments, cytokines including but limited to interferons (e.g., IFN-alpha and IFN-beta), interleukins (e.g., IL-1 through IL-15), tumor necrosis factors (e.g., TNF-alpha and TNF-beta), and GM-CSF find use in the present invention. In yet other embodiments, antibodies (i.e., immunoglobulins), including but not limited to human and humanized antibodies, antibody-derived fragments (e.g., single chain antibodies) of any class, find use in the present invention. In still other embodiments, structural proteins including but not limited to food allergens (e.g., Ber e 1 [Brazil nut allergen] and Ara H1 [peanut allergen]) find use in the present invention. In additional embodiments, the proteins are industrial and/or medicinal enzymes. In some embodiments, preferred classes of enzymes include, but are not limited to proteases, cellulases, lipases, esterases, amylases, phenol oxidases, oxidases, permeases, pullulanases, isomerases, kinases, phosphatases, lactamases and reductases.

[0108] As used herein, “protein” refers to any composition comprised of amino acids and recognized as a protein by those of skill in the art. The terms “protein,” “peptide” and polypeptide are used interchangeably herein. Wherein a peptide is a portion of a protein, those skill in the art understand the use of the term in context. The term “protein” encompasses mature forms of proteins, as well as the pro- and prepro-forms of related, proteins. Prepro forms of proteins, comprise the mature form of the protein having a prosequence operably linked to the amino terminus of the protein, and a “pre-” or “signal” sequence operably linked to the amino terminus of the prosequence.

[0109] As used herein, “wild-type” and “native” proteins are those found in nature. The terms “wild-type sequence,” and “wild-type gene” are used interchangeably herein, to refer to a sequence that is native or naturally occurring in a host cell. In some embodiments, the wild-type sequence refers to a sequence of interest that is the starting point of a protein engineering project.

[0110] As used herein, “protease” refers to naturally-occurring proteases, as well as recombinant proteases. Proteases

are carbonyl hydrolases which generally act to cleave peptide bonds of proteins or peptides. Naturally-occurring proteases include, but are not limited to such examples as α -aminoacylpeptide hydrolase, peptidylamino acid hydrolase, acylamino hydrolase, serine carboxypeptidase, metallo-carboxypeptidase, thiol proteinase, carboxylproteinase and metalloproteinase. Serine, metallo thiol and acid proteases are included, as well as endo and exo-proteases. Indeed, in some preferred embodiments, serine proteases such as chymotrypsin and subtilisin find use. Both of these serine proteases have a catalytic triad comprising aspartate, histidine and serine. In the subtilisin proteases, the relative order of these amino acids reading from the carboxy terminus is aspartate-histidine-serine, while in the chymotrypsin proteases, the relative order of these amino acids reading from the carboxy terminus is histidine-aspartate-serine. Although subtilisins are typically obtained from bacterial, fungal or yeast sources, "subtilisin" as used herein, refers to a serine protease having the catalytic triad of the subtilisin proteases defined above. Additionally, human subtilisins are proteins of human origin having subtilisin catalytic activity, for example the kexin family of human derived proteases. Subtilisins are well known by those skilled in the art for example, *Bacillus amyloliquefaciens* subtilisin (BPN[®]), *Bacillus lentus* subtilisin, *Bacillus subtilis* subtilisin, *Bacillus licheniformis* subtilisin (See e.g., U.S. Pat. No. 4,760,025 (RE 34,606), U.S. Pat. No. 5,204,015, U.S. Pat. No. 5,185,258, EP 0 328 299, and WO89/06279).

[0111] As used herein, functionally similar proteins are considered to be "related proteins." In some embodiments, these proteins are derived from a different genus and/or species (e.g., *B. subtilis* subtilisin and *B. lentus* subtilisin), including differences between classes of organisms (e.g., a bacterial subtilisin and a fungal subtilisin). In additional embodiments, related proteins are provided from the same species. Indeed, it is not intended that the present invention be limited to related proteins from any source(s).

[0112] As used herein, the term "derivative" refers to a protein (e.g., a protease) which is derived from a precursor protein (e.g., the native protease) by addition of one or more amino acids to either or both the C- and N-terminal end(s), substitution of one or more amino acids at one or a number of different sites in the amino acid sequence, and/or deletion of one or more amino acids at either or both ends of the protein or at one or more sites in the amino acid sequence, and/or insertion of one or more amino acids at one or more sites in the amino acid sequence. The preparation of a protease derivative is preferably achieved by modifying a DNA sequence which encodes for the native protein, transformation of that DNA sequence into a suitable host, and expression of the modified DNA sequence to form the derivative protease.

[0113] One type of related (and derivative) proteins are "variant proteins." In preferred embodiments, variant proteins differ from a parent protein and one another by a small number of amino acid residues. The number of differing amino acid residues may be one or more, preferably 1, 2, 3, 4, 5, 10, 15, 20, 30, 40, 50, or more amino acid residues. In one preferred embodiment, the number of different amino acids between variants is between 1 and 10. In particularly preferred embodiments, related proteins and particularly variant proteins comprise at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% amino acid sequence identity. Additionally, a related protein or a variant protein as used herein, refers to a protein that differs from another

related protein or a parent protein in the number of prominent regions. For example, in some embodiments, variant proteins have 1, 2, 3, 4, 5, or 10 corresponding prominent regions which differ from the parent protein. In one embodiment, the prominent corresponding region of a variant produces only a background level of immunogenic response.

[0114] As used herein, "corresponding to," refers to a residue at the enumerated position in a protein or peptide, or a residue that is analogous, homologous, or equivalent to an enumerated residue in another protein or peptide.

[0115] As used herein, "corresponding region" generally refers to an analogous position within related proteins or a parent protein.

[0116] As used herein, the term "analogous sequence" refers to a sequence within a protein that provides similar function, tertiary structure, and/or conserved residues as the protein of interest. In particularly preferred embodiments, the analogous sequence involves sequence(s) at or near an epitope. For example, in epitope regions that contain an alpha helix or a beta sheet structure, the replacement amino acids in the analogous sequence preferably maintain the same specific structure.

[0117] As used herein, "homologous protein" refers to a protein (e.g., protease) that has similar catalytic action, structure, antigenic, and/or immunogenic response as the protein (e.g., protease) of interest. It is not intended that a homolog and a protein (e.g., protease) of interest be necessarily related evolutionarily. Thus, it is intended that the term encompass the same functional protein obtained from different species. In some preferred embodiments, it is desirable to identify a homolog that has a tertiary and/or primary structure similar to the protein of interest, as replacement for the epitope in the protein of interest with an analogous segment from the homolog will reduce the disruptiveness of the change. Thus, in most cases, closely homologous proteins provide the most desirable sources of epitope substitutions. Alternatively, it is advantageous to look to human analogs for a given protein.

[0118] As used herein, "homologous genes" refers to at least a pair of genes from different, but usually related species, which correspond to each other and which are identical or very similar to each other. The term encompasses genes that are separated by speciation (i.e., the development of new species) (e.g., orthologous genes), as well as genes that have been separated by genetic duplication (e.g., paralogous genes).

[0119] As used herein, "ortholog" and "orthologous genes" refer to genes in different species that have evolved from a common ancestral gene (i.e., a homologous gene) by speciation. Typically, orthologs retain the same function in during the course of evolution. Identification of orthologs finds use in the reliable prediction of gene function in newly sequenced genomes.

[0120] As used herein, "paralog" and "paralogous genes" refer to genes that are related by duplication within a genome. While orthologs retain the same function through the course of evolution, paralogs evolve new functions, even though some functions are often related to the original one. Examples of paralogous genes include, but are not limited to genes encoding trypsin, chymotrypsin, elastase, and thrombin, which are all serine proteinases and occur together within the same species.

[0121] The degree of homology between sequences may be determined using any suitable method known in the art (See e.g., Smith and Waterman, Adv. Appl. Math., 2:482 [1981];

Needleman and Wunsch, *J. Mol. Biol.*, 48:443 [1970]; Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444 [1988]; programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, Wis.); and Devereux et al., *Nucl. Acid Res.*, 12:387-395 [1984]).

[0122] For example, PILEUP is a useful program to determine sequence homology levels. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle, (Feng and Doolittle, *J. Mol. Evol.*, 35:351-360 [1987]). The method is similar to that described by Higgins and Sharp (Higgins and Sharp, *CABIOS* 5:151-153 [1989]). Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps. Another example of a useful algorithm is the BLAST algorithm, described by Altschul et al., (Altschul et al., *J. Mol. Biol.*, 215:403-410, [1990]; and Karlin et al., *Proc. Natl. Acad. Sci. USA* 90:5873-5787 [1993]). One particularly useful BLAST program is the WU-BLAST-2 program (See, Altschul et al., *Meth. Enzymol.*, 266:460-480 [1996]). parameters "W," "T," and "X" determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLO-SUM62 scoring matrix (See, Henikoff and Henikoff, *Proc. Natl. Acad. Sci. USA* 89:10915 [1989]) alignments (B) of 50, expectation (E) of 10, M⁵, N⁴, and a comparison of both strands.

[0123] As used herein, "percent (%) nucleic acid sequence identity" is defined as the percentage of nucleotide residues in a candidate sequence that are identical with the nucleotide residues of the sequence.

[0124] As used herein, the term "hybridization" refers to the process by which a strand of nucleic acid joins with a complementary strand through base pairing, as known in the art.

[0125] As used herein, "maximum stringency" refers to the level of hybridization that typically occurs at about T_m-5° C. (5° C. below the T_m of the probe); "high stringency" at about 5° C. to 10° C. below T_m; "intermediate stringency" at about 10° C. to 20° C. below T_m; and "low stringency" at about 20° C. to 25° C. below T_m. As will be understood by those of skill in the art, a maximum stringency hybridization can be used to identify or detect identical polynucleotide sequences while an intermediate or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs.

[0126] In some embodiments, "equivalent residues" are defined by determining homology at the level of tertiary structure for a precursor protein (i.e., protein of interest) whose tertiary structure has been determined by x-ray crystallography. Equivalent residues are defined as those for which the atomic coordinates of two or more of the main chain atoms of a particular amino acid residue of the precursor protein and another protein are within 0.13 nm and preferably 0.1 nm after alignment. Alignment is achieved after the best model has been oriented and positioned to give the maximum overlap of atomic coordinates of non-hydrogen protein atoms of the protein. In most embodiments, the best model is the crystallographic model giving the lowest R factor for experimental diffraction data at the highest resolution available.

[0127] In some embodiments, modification is preferably made to the "precursor DNA sequence" which encodes the amino acid sequence of the precursor enzyme, but in alternative embodiments, it is made by the manipulation of the precursor protein. In the case of residues which are not conserved, the replacement of one or more amino acids is limited to substitutions which produce a variant which has an amino acid sequence that does not correspond to one found in nature. In the case of conserved residues, such replacements should not result in a naturally-occurring sequence. Derivatives provided by the present invention further include chemical modification(s) that change the characteristics of the protease.

[0128] In some preferred embodiments, the protein gene is ligated into an appropriate expression plasmid. The cloned protein gene is then used to transform or transfect a host cell in order to express the protein gene. This plasmid may replicate in hosts in the sense that it contains the well-known elements necessary for plasmid replication or the plasmid may be designed to integrate into the host chromosome. The necessary elements are provided for efficient gene expression (e.g., a promoter operably linked to the gene of interest). In some embodiments, these necessary elements are supplied as the gene's own homologous promoter if it is recognized, (i.e., transcribed by the host), a transcription terminator (a polyadenylation region for eukaryotic host cells) which is exogenous or is supplied by the endogenous terminator region of the protein gene. In some embodiments, a selection gene such as an antibiotic resistance gene that enables continuous cultural maintenance of plasmid-infected host cells by growth in antimicrobial-containing media is also included.

[0129] In embodiments involving proteases, variant protease activity is determined and compared with the protease of interest by examining the interaction of the protease with various commercial substrates, including, but not limited to casein, keratin, elastin, and collagen. Indeed, it is contemplated that protease activity will be determined by any suitable method known in the art. Exemplary assays to determine protease activity include, but are not limited to, succinyl-Ala-Ala-Pro-Phe-para nitroanilide (SAAPFpNA) (citation) assay; and 2,4,6-trinitrobenzene sulfonate sodium salt (TNBS) assay. In the SAAPFpNA assay, proteases cleave the bond between the peptide and p-nitroaniline to give a visible yellow color absorbing at 405 nm. In the TNBS color reaction method, the assay measures the enzymatic hydrolysis of the substrate into polypeptides containing free amino groups. These amino groups react with TNBS to form a yellow colored complex. Thus, the more deeply colored the reaction, the more activity is measured. The yellow color can be determined by various analyzers or spectrophotometers known in the art.

[0130] Other characteristics of the variant proteases can be determined by methods known to those skilled in the art. Exemplary characteristics include, but are not limited to thermal stability, alkaline stability, and stability of the particular protease in various substrate or buffer solutions or product formulations.

[0131] When combined with the enzyme stability assay procedures disclosed herein, mutants obtained by random mutagenesis can be identified which demonstrated either increased or decreased alkaline or thermal stability while maintaining enzymatic activity.

[0132] Alkaline stability can be measured either by known procedures or by the methods described herein. A substantial change in alkaline stability is evidenced by at least about a 5%

or greater increase or decrease (in most embodiments, it is preferably an increase) in the half-life of the enzymatic activity of a mutant when compared to the precursor protein.

[0133] Thermal stability can be measured either by known procedures or by the methods described herein. A substantial change in thermal stability is evidenced by at least about a 5% or greater increase or decrease (in most embodiments, it is preferably an increase) in the half-life of the catalytic activity of a mutant when exposed to a relatively high temperature and neutral pH as compared to the precursor protein.

[0134] Many of the protein variants of the present invention are useful in formulating various compositions for numerous applications, ranging from personal care to industrial production. For example, a number of known compounds are suitable surfactants useful in detergent compositions comprising the protein mutants of the present invention. These include nonionic, anionic, cationic, anionic or zwitterionic detergents (See e.g., U.S. Pat. No. 4,404,128, U.S. Pat. No. 4,261,868, and U.S. Pat. No. 5,204,015). Thus, it is contemplated that proteins characterized and modified as described herein will find use in various detergent applications. Those in the art are familiar with the different formulations which find use as cleaning compositions. In addition to typical cleaning compositions, it is readily understood that the protein variants of the present invention find use in any purpose that native or wild-type proteins are used. Thus, these variants can be used, for example, in bar or liquid soap applications, dishcare formulations, surface cleaning applications, contact lens cleaning solutions and/or products, peptide hydrolysis, waste treatment, textile applications, as fusion-cleavage enzymes in protein production, etc. For example, the variants of the present invention may comprise, in addition to decreased allergenicity, enhanced performance in a detergent composition (as compared to the precursor). Indeed, it is not intended that the variants of the present invention be limited to any particular use. As used herein, "enhanced performance in a detergent" is defined as increasing cleaning of certain enzyme sensitive stains (e.g., grass or blood), as determined by usual evaluation after a standard wash cycle.

[0135] In some embodiments, proteins, particularly enzymes, provided by the means of the present invention are can be formulated into known powdered and liquid detergents having pH between 6.5 and 12.0 at levels of about 0.01 to about 5% (preferably 0.1% to 0.5%) by weight. In some embodiments, these detergent cleaning compositions further include other enzymes such as proteases, amylases, cellulases, lipases or endoglycosidases, as well as builders and stabilizers.

[0136] The addition of proteins to conventional cleaning compositions does not create any special use limitations. In other words, any temperature and pH suitable for the detergent are also suitable for the present compositions, as long as the pH is within the above range, and the temperature is below the described protein's denaturing temperature. In addition, proteins of the invention find use in cleaning compositions without detergents, again either alone or in combination with builders and stabilizers.

[0137] In one embodiment, the present invention provides compositions for the treatment of textiles that includes variant proteins of the present invention. The composition can be used to treat for example silk or wool (See e.g., RE 216,034; EP 134,267; U.S. Pat. No. 4,533,359; and EP 344,259). In some embodiments, these variants are screened for proteolytic activity according to methods well known in the art.

[0138] As indicated above, in preferred embodiments, the proteins of the present invention exhibit modified immunogenic responses (e.g., antigenicity and/or immunogenicity) when compared to the native proteins encoded by their precursor DNAs. In some preferred embodiments, the proteins (e.g., proteases) exhibit reduced allergenicity. Those of skill in the art readily recognize that the uses of the proteases of this invention will be determined, in large part, on the immunological properties of the proteins. For example, proteases that exhibit reduced immunogenic responses can be used in cleaning compositions. An effective amount of one or more protease variants described herein find use in compositions useful for cleaning a variety of surfaces in need of proteinaceous stain removal. Such cleaning compositions include detergent compositions for cleaning hard surfaces, detergent compositions for cleaning fabrics, dishwashing compositions, oral cleaning compositions, and denture cleaning compositions.

[0139] An effective amount of one or more related and/or variant proteins with reduced allergenicity/immunogenicity, ranked according to the methods of the present invention find use in various compositions that are applied to keratinous materials such as nails and hair, including but not limited to those useful as hair spray compositions, hair shampoo and/or conditioning compositions, compositions applied for the purpose of hair growth regulation, and compositions applied to the hair and scalp for the purpose of treating seborrhea, dermatitis, and/or dandruff.

[0140] In additional embodiments, effective amount(s) of one or more protease variant(s) described herein find use in included in compositions suitable for topical application to the skin or hair. These compositions can be in the form of creams, lotions, gels, and the like, and may be formulated as aqueous compositions or may be formulated as emulsions of one or more oil phases in an aqueous continuous phase.

[0141] In addition, the related and/or variant proteins with reduced allergenicity/immunogenicity find use in other applications, including pharmaceutical applications, drug delivery applications, and other health care applications.

DETAILED DESCRIPTION OF THE INVENTION

[0142] The present invention provides means to assess immune response profiles of populations. In particular, the present invention provides means to qualitatively assess the immune response of human populations, wherein the immune response directed against any protein of interest is analyzed. The present invention further provides means to rank proteins based on their relative immunogenicity. In addition, the present invention provides means to create proteins with reduced immunogenicity for use in various applications.

[0143] The present invention provides methods to assess the overall immunogenic potential of any protein by an analysis of the response rate of individual donors to a set of peptides describing the protein of interest. These methods find use in select the least immunogenic isomer of related proteins. In addition, these methods find use in guiding the development of variant proteins with reduced immunogenicity.

[0144] In some preferred embodiments, population-based immune response profiles find use in these methods of developing proteins that have reduced immunogenicity. In addition, the present invention provides means to determine whether or not a particular population has been exposed to a protein of interest, as well as the level of the immune responses among the individuals in the population. This

determination provides information useful in the development of proteins with altered immunogenicity characteristics that are desired in applications such as bioproducts, food and feed, protein therapeutics, personal care, healthcare products, detergents, and other consumer-associated goods.

[0145] The present invention provides novel means to study the immune responses of populations. As indicated herein, potency determinations for applications involving proteins for administration to humans currently utilize non-human animal models. In addition, T-cell epitopes determinations based on algorithms do not provide the needed information that is provided by the application of the present invention. Indeed, the present invention provides means to assess the immune response profiles of individuals, as well as populations, which provides important information for the rational design and development of protein-containing products.

[0146] By analyzing the background response and the structure value of proteins, the immunological "history" of any protein of interest can be determined on a population basis. A high background response indicates population pre-exposure (i.e., more than approximately 4% of the population exhibits immune response to the protein tested). A high structure value indicates a potential immunogen for proteins with low background values, and recent, frequent, and "high quality" immune responses when the protein has a high background. In some embodiments, "high quality" immune responses are observed, due to high levels of immunogen, a robust immune response against the immunogen, and/or a response potentiated by a strong adjuvant.

[0147] In some embodiments, low structure values with high backgrounds represent fading immune memory responses, infrequent responses in the population, tolerance induction by exogenous antigen, and/or responses to proteins that are highly diverse (i.e., which may also be a product of a "fading" memory response). It is contemplated that common, non-allergenic food proteins are represented in this type of response profile. In addition, proteins with low structure values and low backgrounds represent comparatively non-immunogenic proteins with no memory response in the population and/or proteins that the human population is tolerized against. In some preferred embodiments, proteins with low background levels of exposure are modified so as to be made "hypoallergenic" (i.e., they do not induce an immune response or induce a lower response, upon exposure to a human or other animal).

[0148] To establish a background value for proteins not encountered by the general donor population, the I-MUNE® assay was performed on 11 industrial enzymes including proteases, amylases, laccases, and chitinases (See, Mathies, *Tenside Surf. Det.*, 34:450-454 [1997]). One of the proteases was tested twice using peptides produced in two different formats (PepSet versus purified peptides from Mimotopes). The number of donors tested per peptide set varied from 19 to 113. The number of peptides in each peptide set varied from 80 to 188. A response was tabulated when the stimulation index (S.I. or SI) for an individual peptide was 2.95 or greater. The percent of donors in the tested donor set responding to each peptide was calculated. The average percent response per peptide for each tested protein was calculated, and is shown graphed versus the number of donors tested (See, FIG. 11). The correlation coefficient was $R^2=0.86$. The slope of the correlation reveals the average accumulation rate of responses as 3.01%. Therefore, for any given donor tested with peptides derived from industrial proteins, an average of

three peptides out of 100 will return a positive ($SI \geq 2.95$) response. This average response rate includes both epitope peptides (see below) and the non-epitope peptides.

[0149] Background responses were also calculated by averaging the percent response per peptide in the completed dataset. Averaging the background responses for the 12 tests, the value is 3.15 ± 0.45 (average \pm standard error) which is consistent with the value determined by the slope of the correlation trendline.

[0150] During the development of the present invention, a group of proteins was selected based on their presumed exposure in the general human population. These proteins included Brazil nut allergen Ber e 1, and staphylokinase. Brazil nut allergy occurs in <1% of the population, but exposure to Brazil nuts in food is widespread (Sicherer and Sampson, *Curr. Opin. Pediatr.*, 12:567-573 [2000]). In addition, the rate of staphylokinase-specific T-cell responses in human peripheral blood cell cultures increases with age, with 30% of young donors responding and greater than 70% of donors over age 40 responding (Warmerdam et al., *J. Immunol.* 168: 155-161 [2002]). Peptide sets to these four proteins were tested with samples from local community blood banks. The background responses to all four of these proteins were higher than the average responses found in the 11 industrial enzymes. This is shown as both a higher overall percent background response, and as a higher frequency of responses per peptide as compared to the expected values based on data from the 11 industrial enzymes from FIG. 11. The background responses to staphylokinase were significantly higher. This result is consistent with the presumed higher exposure rate to these proteins in the donor pool. The background responses to Ber e 1 were higher than the industrial protein average, but were not significantly different. The increase in background values as compared to the industrial protein values is due to the contribution of CD4+ memory responses in the donor population that increase the amplitude, number and complexity of the overall response to a given protein (Kuhns et al., *Proc. Natl. Acad. Sci. USA* 97:12711-12716 [2000]; Muraro et al., *J. Immunol.*, 164:5474-5481 [2000]; and Vanderlugt and Miller, *Nat. Rev. Immunol.*, 2:85-95 [2002]). Therefore, a higher background rate represents a higher level of sensitization to the tested protein. However, it is not intended that the present invention be limited to any particular mechanism regarding the overall responses against these proteins. For the proteins described herein, it can be concluded that there is significant exposure of our donor population to staphylokinase, and less exposure to Ber e 1. The background responses to Ber e 1 are suggestive of exposure to the proteins, but not at the levels of staphylokinase.

[0151] In addition to these proteins, peptide sets describing human proteins were also tested in during the development of the present invention. These proteins included interferon- β (IFN- β), a cytokine widely expressed during immune responses, thrombopoietin (TPO), a cytokine whose expression is restricted to the bone marrow, and a soluble recombinant cytokine receptor molecule (tumor necrosis factor receptor-1; TNF-R1). Background responses to all four of these proteins were similar to the industrial enzyme background data, suggesting that the donors were responding to the peptides in these sets as if they were unexposed, or "naïve" to these proteins. These data are consistent with the ignorance mechanism of peripheral tolerance to these particular proteins.

[0152] In additional embodiments, assessment of the T-cell and/or B-cell epitopes associated with the test proteins is made. In further embodiments, this assessment is utilized in developing rational changes in such epitopes to reduce the immunogenicity/allergenicity of the test proteins (i.e., to produce variant proteins with reduced immunogenicity). These variant proteins then find use in various applications, including but not limited to bioproducts, protein therapeutics, food and feed, personal care, detergents, and other consumer-associated products, as well as in other treatment regimens, diagnostics, etc.

[0153] In preferred embodiments, the method uses dendritic cells as antigen-presenting cells, 15-mer peptides offset by 3 amino acids that encompass the entire sequence of the protein, and CD4+ T cells from the dendritic cell donors. A "positive" response is tallied if the average CPM of tritiated thymidine incorporation for a particular peptide is greater than or equal to 2.95 times the background CPM. The results for each peptide are tabulated for a large donor set that should reflect general HLA allele frequencies (with some variations). A statistical calculation based on the determination of "difference from linearity" is performed, and this structure value is used to rank the relative immunogenicity of these proteins. As indicated herein, the ranking results obtained using the methods of the present invention closely reflect immunogenicity determinations (i.e., by the MID assay of Sarlo, *Toxicol. Sci.*, 72:229 [1997], *supra*) and allergenicity of these proteins as respiratory allergens when determined in occupationally exposed workers (See, Sarlo, *supra*), or in the GPIT or MINT assay systems (See, Robinson, [1998] *supra*).

[0154] During the development of the present invention, structure values for a set of proteins including three known immunogens were found to be comparatively high, indicating that these proteins might be capable of inducing immune responses in a significant number of exposed people. Conversely, the structure value for a mouse VH 36-60 gene family member was low, commensurate with its predicted immunogenicity (See, Olsson, *J. Theor. Biol.*, 151:111-122 [1991]). Finally, the structure value determined for β 2-microglobulin was low, as would be expected given that this molecule is presumed to be subject to both peripheral and central tolerance mechanisms (See, Guery et al., *J. Immunol.*, 154:545-554 [1995]).

[0155] In additional experiments, as described herein, 25 diverse proteins were tested. These data provide a framework for validating the present invention; it is not intended that the present invention be limited to these 25 proteins. Indeed, the present invention finds use in the analysis of any suitable protein of interest in any suitable population of interest. As with the initial experiments described above, the proteins were tested in the I-MUNE® assay system described herein, and structure values were determined. For these 25 proteins, the structure values and background responses delineated four subsets of proteins with varying attributes of interest among the population tested. The ranking method described herein was validated on those proteins with low background responses. Furthermore, all of the proteins tested were compared with those having high background responses. In addition to ranking the potential immunogenicity of the proteins, these embodiments provide information regarding the type of immune response the general population has mounted against the tested proteins.

[0156] The comparative immunogenicity of proteins tested in the I-MUNE® assay system of the present invention assume that proteins would be compared *in vivo* at the same dose, in the same formulation, in a matched set of donors, and over the same dose course. This analysis also precludes any processing and/or presentation differences in the proteins, as well as general physical and structural properties (i.e., stability and activity).

[0157] The present invention provides methods that facilitate the localization of T cell epitopes in any protein of interest. For example, in some preferred embodiments, CD4+ T cell epitopes are determined in the absence of individuals sensitized to the test protein. Thus, modification of the peptide epitopes such that reduced response rates predicted to be effective in humans are achievable without the need to sensitize volunteers. In some embodiments, an analysis of donor responses to the modified peptide variants is used to calculate structure values for the new protein. For example, as shown in FIG. 9, a protease variant constructed to have a reduced structure value induced significantly less proliferation *in vitro* when compared to the parent protein.

[0158] The present invention provides distinct advantages in determining the immunogenicity of proteins. In contrast to the present invention, testing of protein variants designed to be less immunogenic by virtue of provoking fewer responses *in vitro* with large replicates of human donors cannot be rationally tested in guinea pigs or mice. Transgenic mice are limited in their utility, due to the fact that they typically do not express more than one HLA allele, and even then it is often not expressed in a correct context.

[0159] Although the ranking of proteins does not imply any fold potency differences, potency differences in guinea pig and mouse models are notoriously inaccurate, susceptible to inter-laboratory as well as inter-experiment variability, and are strain dependent in mice. Indeed, potency determination in animals, particularly guinea pigs is a subjective science, at best. Currently, there is no reliable method to determine potency. However, the present invention provides a means to make potency determinations by extrapolating data based on the alignment of the data determined using the methods of the present method with data obtained from animal experiments. Despite the fact that these potency values are subject to the same inherent inaccuracies as the animal data used to standardize the structure value results, the present invention provides much-improved means to assess immunogenicity, particularly in humans, and determine how best to reduce the immunogenicity of proteins.

[0160] Furthermore, the present invention provides means to determine the relative immunogenicity of proteins in human subjects (or other animals) without the necessity of exposing the subjects to the protein of interest. Thus, there is no risk of sensitizing individuals to potentially allergenic/immunogenic substances in order to make the determinations. Importantly, the present invention provides means to rank the immunogenicity of proteins relative to each other, as well as assess the immune response profiles of populations. Indeed, the present invention provides the means to select and/or develop reduced immunogenicity proteins and direct the rational modification of proteins, to create and test hypo-immunogenic variants that are suitable for use in humans and other animals, particularly in humans. In addition, the present invention provides PBMC proliferation assay methods that have been shown to provide data that are correlative with known immunogenic and non-immunogenic proteins, as

shown herein. This assay has also been shown to accurately detect immune-responsive modifications in CD4⁺ T-cell epitopes. It is also contemplated that this assay will find use in determining which donors are more likely to respond to a protein of interest due to the presence of specific HLA molecules. Furthermore, the PBMC proliferation assay finds use in detecting the effects of tolerance induction in the general community donor population. It is also contemplated that the methods of the present invention will find use in the screening of large replicates of whole protein molecules, as well as in validating/verifying I-MUNE® assay-guided modifications on a whole protein basis.

EXPERIMENTAL

[0161] The following examples serve to illustrate certain preferred embodiments and aspects of the present invention and are not to be construed as limiting the scope thereof.

[0162] In the experimental disclosure which follows, the following abbreviations apply: eq (equivalents); M (Molar); μ M (micromolar); N (Normal); mol (moles); mmol (millimoles); μ mol (micromoles); nmol (nanomoles); g (grams); mg (milligrams); kg (kilograms); μ g (micrograms); L (liters); ml (milliliters); μ l (microliters); cm (centimeters); mm (millimeters); μ m (micrometers); nm (nanometers); °C. (degrees Centigrade); h (hours); min (minutes); sec (seconds); msec (milliseconds); xg (times gravity); Ci (Curies); PMBC (peripheral blood mononuclear cells); OD (optical density); Dulbecco's phosphate buffered solution (DPBS); HEPES (N-[2-Hydroxyethyl]piperazine-N-[2-ethanesulfonic acid]); HBS (HEPES buffered saline); SDS (sodium dodecylsulfate); Tris-HCl (tris[Hydroxymethyl]aminomethane-hydrochloride); Klenow (DNA polymerase I large (Klenow) fragment); rpm (revolutions per minute); EGTA (ethylene glycol-bis(β -aminoethyl ether) N,N,N',N'-tetraacetic acid); EDTA (ethylenediaminetetraacetic acid); SPT+ (skin prick test positive); SPT- (skin prick test negative); ATCC (American Type Culture Collection, Rockville, Md.); Cedar Lane (Cedar Lane Laboratories, Ontario, Canada); Gibco and Gibco/Life Technologies (Gibco/Life Technologies, Grand Island, N.Y.); Sigma (Sigma Chemical Co., St. Louis, Mo.); Pharmacia (Pharmacia Biotech, Piscataway, N.J.); Procter & Gamble (Procter and Gamble, Cincinnati, Ohio); Genencor (Genencor International, Palo Alto, Calif.); Endogen (Endogen, Woburn, Mass.); Cedarlane (Cedarlane, Toronto, Canada); Dynal (Dynal, Norway); Novo (Novo Industries A/S, Copenhagen, Denmark); Biosynthesis (Biosynthesis, Louisville, Tex.); TriLux Beta, (TriLux Beta, Wallac, Finland); DuPont/NEN (DuPont/NEN Research Products, Boston, Mass.); TomTec (Hamden, Conn.); Greer (Greer Laboratories, Lenoir, N.C.); Berlex (Berlex, Montville, N.J.); Pierce (Pierce Biotechnology, Inc., Rockford, Ill.); Corning (Corning, Inc., Acton, Mass.); and Stratagene (Stratagene, La Jolla, Calif.).

Peptides

[0163] All peptides were obtained from a commercial source (Mimotopes, San Diego, C-A). For the I-MUNE® assay system described herein, 15-mer peptides offset by 3 amino acids that described the entire sequence of the proteins of interest were synthesized in a multipin format (See, Maeji et al., J. Immunol. Meth., 134:23-33 [1990]). Peptides were resuspended in DMSO at approximately 1 to 2 mg/ml, and stored at -70° C. prior to use. Each peptide was tested at least in duplicate, although for small peptide sets (e.g., Ber e 1), the

peptides were routinely tested in triplicate. The results for each peptide were averaged and the stimulation index (SI) was calculated for each peptide.

Protein Sequences

[0164] Amino acid sequences from the following well-characterized industrial enzymes were tested and rank ordered using the methods of the present invention. The sequences of these proteins are publicly available from databases such as Medline. The proteins that are described herein in greatest detail include *B. lentus* subtilisin (Swissprot accession number P29600), BPN Y217L (Swissprot accession number P00782), ALCALASE® enzyme (Swissprot accession number P00780), and alpha-amylase (Swissprot accession number P06278).

Human Donor Blood Samples

[0165] Volunteer donor human blood buffy coat samples were obtained from two commercial sources (Stanford Blood Center, Palo Alto, Calif., and the Sacramento Medical Foundation, Sacramento, Calif.). Buffy coat samples were further purified by density separation. Each sample was HLA typed for HLA-DR and HLA-DQ using a commercial PCR-based kit (Bio-Synthesis). The HLA DR and DQ expression in the donor pool was determined to not be significantly different from a North American reference standard (Mori et al., Transplant., 64:1017-1027 [1997]). However, the donor pool did show evidence of slight enrichments for ethnicities common to the San Francisco Bay Area.

Preparation of Dendritic Cells and CD4⁺ T-Cells

[0166] Monocytes were purified by adherence to plastic in AIM V medium (Gibco/Life Technologies). Adherent cells were cultured in AIM V media containing 500 units/ml of recombinant human IL-4 (Endogen) and 800 units/ml recombinant human GM-CSF (Endogen) for 5 days. On day 5, recombinant human IL-1 α (Endogen) and recombinant human TNF- α (Endogen) were added to 50 units/ml and 0.2 units/ml, respectively. On day 7, the fully matured dendritic cells were treated with 50 μ g/ml mitomycin C (Sigma) for 1 hour at 37° C. Treated dendritic cells were dislodged with 50 mM EDTA in PBS, washed in AIM V medium, counted, and resuspended in AIM V media at 2 \times 10⁵ cells/ml.

[0167] CD4⁺ T-cells were purified by negative selection from frozen aliquots of human peripheral blood mononuclear cells (PBMC) using Collect CD4 columns (Cedarlane). CD4⁺ T-cell populations were routinely >80% pure and >95% viable as judged by trypan blue (Sigma) exclusion. CD4⁺ T-cells were resuspended in AIM V media at 2 \times 10⁶ cells per ml.

PBMC Assay Preparation

[0168] Community donor PBMC samples were purchased from the Stanford University Blood Center (Palo Alto, Calif.) or from BloodSource (Sacramento, Calif.). Each sample tested in the PBMC assay was tested for common human bloodborne pathogens. PBMCs obtained from the donor samples were isolated from the buffy coats by differential centrifugation using Lymphocyte Separation Media (Gibco). Human IFN-beta (Betaseron) was purchased from Berlex. Food allergen extracts were purchased from Greer. All proteins were tested for the presence of endotoxin using a commercially available kit (Pierce). Endotoxin was removed

using the DeToxiGel system (Pierce). All samples were adjusted to 1-2 mg/ml protein in PBS and were filter-sterilized. Proteolytic enzymes were treated with PMSF three times prior to inclusion in the assays.

I-MUNE® Assay Conditions

[0169] CD4⁺ T-cells and dendritic cells were plated in round-bottomed 96 well format plates at 100 µl of each cell mix per well. Peptide was added to a final concentration of approximately 5 µg/ml in 0.25-0.5% DMSO. Control wells contained 0.5% DMSO without added peptide. Each peptide was tested in duplicate. Cultures were incubated at 37° C., in 5% CO₂ for 5 days. On day 5, 0.5 uCi of tritiated thymidine (NEN DuPont) was added to each well. On day 6, the cultures were harvested onto glass fiber mats using a TomTec manual harvester (TomTec), then processed for scintillation counting. Proliferation was assessed by determining the average counts per minute (CPM) value for each set of duplicate wells (TriLux Beta). This method is also described in U.S. Pat. No. 6,218,165 and Stickler et al., J. Immunother. 23: 654-660 (2000), both of which are herein incorporated by reference.

I-MUNE® Assay Data Analysis

[0170] For each individual buffy coat sample, the average CPM values obtained in the I-MUNE® assay for all of the peptides were analyzed. The average CPM values for each peptide were divided by the average CPM value for the control (DMSO only) wells to determine the “stimulation index” (SI). Donors were tested with each peptide set until an average of at least two responses per peptide were compiled. The data for each protein was graphed showing the percent responders to each peptide within the set. A positive response was collated if the SI value was equal to or greater than 2.95. This value was chosen as it approximates a difference of three standard deviations in a normal population distribution. For each protein assessed, positive responses to individual peptides by individual donors were compiled. To determine the background response for a given protein, the percent responders for each peptide in the set were averaged and a standard deviation was calculated. SI values for each donor were compiled for each peptide set, and the percent of responders reported. The average background response rate for each peptide set was calculated by averaging the percent response for all of the peptides in the set. Statistical significance was calculated using Poisson statistics for the number of responders to each peptide within the dataset. Different statistical methods were used as described herein. The response to a peptide was considered significant if the number of donors responding to the peptide was different from the Poisson distribution defined by the dataset with a p<0.05.

Peptide Binding Analysis

[0171] In addition to the above I-MUNE® assay, peptide binding assays were also performed. The peptide binding assay used during the development of the present invention is known in the art (Southwood et al., J. Immunol., 160:3363-3373 [1998]). Briefly, HLA-DR and -DQ molecules were purified from a panel of EBV transformed cell lines. A competition assay was performed with a characterized standard peptide, and the unknown peptide. The amount of unknown

peptide required to compete 50% of the standard peptide binding was then determined (indicated as the IC₅₀).

Statistical Methods

[0172] Statistical significance of peptide responses were calculated based on Poisson statistics. The average frequency of responders was used to calculate a Poisson distribution based on the total number of responses and the number of peptides in the set. A response was considered significant if p<0.05. In addition, two-tailed Student’s t-tests with unequal variance, were performed. For epitope determination using data with low background response rates, a conservative Poisson based formula was applied:

$$= 1 - e^{-n} \left(1 - \sum_{x=0}^{n-1} \frac{\lambda^x e^{-\lambda}}{x!} \right)$$

where n=the number of peptides in the set, x=the frequency of responses at the peptide of interest, and λ=the median frequency of responses within the dataset. For epitope determinations based on data with a high background response rate, the less stringent Poisson based determination

$$1 - \left(\sum_{i=0}^x \frac{\lambda^i e^{-\lambda}}{i!} \right)$$

was used, where λ=the median frequency of responses in the dataset, and x=the frequency of responses at the peptide of interest.

[0173] In additional embodiments, the structure determination was calculated based on the following formula:

$$\sum \left| f(i) - \frac{1}{p} \right|$$

wherein Σ (upper case sigma) is the sum of the absolute value of the frequency of responses to each peptide minus the frequency of that peptide in the set; f (i) is defined as the frequency of responses for an individual peptide; and p is the number of peptides in the peptide set.

[0174] This equation returns a value between 0 and 2, which is equal to the “Structure Value.” A value of 0 indicates that the results are completely without structure, and a value of 2.0 indicates all structure is highly structured around a single area. The closer the value is to 2.0, the more immunogenic the protein. Thus, a low value indicates a less immunogenic protein.

HLA Types Within the Donor Pool

[0175] HLA-D and DQ types were analyzed for associations with responses to defined epitope peptides. A Chi-squared analysis, with one degree of freedom was used to determine significance. Where an allele was present in both the responder and non-responder pools, a relative risk was calculated.

[0176] The HLA-DRB1 allelic expression was determined for approximately 185 random individuals. HLA typing was performed using low-stringency PCR determinations. PCR

reactions were performed as directed by the manufacturer (Bio-Synthesis). The data compiled for the Stanford and Sacramento samples were compared the "Caucasian" HLA-DRB1 frequencies as published (See, Marsh et al., *HLA Facts Book*, The Academic Press, San Diego, Calif. [2000], page 398, FIG. 1). The donor population in these communities is enriched for HLA-DR4 and HLA-DR15. However, the frequencies of these alleles in these populations are well within the reported range for these two alleles (5.2 to 24.8% for HLA-DR4 and 5.7 to 25.6% for HLA-DR15). Similarly, for HLA-DR3, -DR7 and DR11, the frequencies are lower than the average Caucasian frequency, but within the reported ranges for those alleles. Also of note, HLA0DR15 is found at a higher frequency in ethnic populations that are heavily represented in the San Francisco Bay Area.

PBMC Assay Conditions

[0177] PBMC were adjusted to 4×10^6 per ml in 5% heat-inactivated human AB serum-containing RPMI medium. Cultures were seeded at 2 mls per well in a 24-well plate (Costar). Purified proteins were added, and the bulk cultures were incubated at 37° C., in 5% CO₂ for 5 days. This incubation period was selected based on preliminary testing that involved testing cultures at 4, 5, 6 and 7 days. While the optimum responses were seen at 5 days for most proteins, there was an exception, in that robust secondary responses to proteins such as tetanus toxoid often peaked at day 4. Thus, in some embodiments, a shorter (or longer) incubation period finds use in the present invention.

[0178] On day 5, the bulk cultures were resuspended and 100 ul aliquots of each culture were replicatively plated into a 96-well plate. From 4 to 12 replicates were performed for each bulk culture. Tritiated thymidine was added at 0.25 uCi per well, and the replicates were cultured for 6 hours. Cultures were harvested to glass filtermats (Wallac) and the samples were counted in a scintillation counter (Wallac TriBeta). The CPMs determined for each bulk culture were averaged. A control well with no added protein provided background CPM for each donor. A stimulation index for each test was calculated by dividing the experimental CPM by the control. An SI of 1.0 indicated that there was no proliferation above the background level.

Example 1

Compiled Results for Four Known Respiratory Allergens

[0179] In this Example, the results obtained using the I-MUNE® assay and analysis methods of the present invention described above, to test four known respiratory allergens are described.

[0180] A. Alpha Amylase

[0181] In these experiments, 82 individuals were tested with peptides derived from the alpha amylase sequence. The background response to peptides in this set was 2.80+/-3.69%, well within the overall average obtained in tests with 11 industrial enzymes of 3.16+/-1.57 (data not shown). Prominent responses were noted to amino acids 34-48, 160-174, and 442-456 of alpha amylase (See, FIG. 2). All three of these responses were highly significant above the background response ($p < 0.0001$).

[0182] B. *B. lentus* Subtilisin

[0183] In these experiments, 65 individuals were tested with two replicate peptide sets for this protein and the results

were compiled. The background for this peptide set was found to be 3.45+/-2.90%, but within the established range. Prominent responses were noted at amino acids 160-174 ($p = 0.0003$) (See, FIG. 3).

[0184] C. BPN^Y217L

[0185] In these experiments, 113 individuals were tested with two peptide sets. The compiled average for this dataset was 3.62%. Prominent responses were noted at amino acids 70-84 and 109-123 (See, FIG. 4). A region of responses was also noted around amino acid 154.

[0186] D. ALCALASE® Enzyme

[0187] In these experiments, 92 individuals were tested with peptides derived from this enzyme. The background response to this protein was found to be low (2.35%). The same peptide set was tested in two temporally spaced analyses, and the data were compiled. In addition, there were significantly more peptides returning no response within the set for this protein. A prominent response was noted at amino acids number 19-33 ($p < 0.0001$) (See, FIG. 5).

Example 2

Structure Calculations

[0188] This Example describes the structure values obtained for the four enzymes tested. Structure values are dependent on the number of donors tested. A zero response rate across most of the dataset results in a structure value of ~1.0. The same number of responses at each peptide yields a structure value of 0. Therefore, it is important to test a peptide set until responses across the majority of the dataset are accumulated, in order for the data to accurately reflect responsiveness to particular peptides and peptide regions. The structure value decreases with increasing numbers of donors tested until a plateau level is reached, usually between 2-3 responses per peptide (See, FIG. 6). The plateau structure value must be used for comparing structure values.

[0189] For each of the enzymes tested, the compiled responses were used to calculate structure within the dataset. The structure values were: 0.81 for amylase, 0.72 for ALCALASE® enzyme, 0.64 for *B. lentus* subtilisin, and 0.53 for BPN^Y217L, as shown in Table 1.

TABLE 1

Structure Determination for Four Respiratory Allergens					
Enzyme	Peptides	n	Responses per peptide	Number of epitope regions	Structure value
Amylase	157	82	2.29	3	0.81
<i>B. lentus</i> subtilisin	86	65	2.24	1	0.64
ALCALASE®	88	92	2.16	1	0.72
BPN ^Y 217L	88	113	3.65	2	0.53

[0190] These results indicate that there is more activity induced by the amylase peptide set, when CD4+ T cell activation is measured by a level of proliferation resulting in an SI of 2.95 or greater, as compared to activity measured using the other peptide sets. The result for BPN^Y217L indicates that the peptide set derived from the sequence of this protein was the least active, with the lowest amount of structure. The structure values rank order the four tested proteins as:

[0191] amylase > ALCALASE® enzyme > *B. lentus* subtilisin > BPN^Y217L

Example 3

Comparison to Animal Models

[0192] As indicated above, two animal models have been used for the prediction of allergenicity and immunogenicity of industrial proteins. Thus, in this Example, comparisons made between these two animal models and the methods of the present invention are described. Both the guinea pig (GPIT) and BDF1 mouse (MINT) models rank the proteins in the order: amylase>ALCALASE® enzyme>*B. lentus* subtilisin>BPN[®] Y217L. However, the relative values differ. FIG. 7 shows the structure values graphed versus the GPIT (Panel A) and MINT (Panel B) potency values. Human cell-based structure data obtained from using the methods of the present invention indicated a correlation with both methods (R values of 0.86 and 0.84, respectively).

Example 4

Structure Values of Additional Proteins

[0193] In this Example, structure values obtained for additional proteins are described. For example, structure values were calculated for Ber e 1 (i.e., the major allergen found in Brazil nuts), human interferon-beta (IFN- β), human thrombopoietin (Tpo), a mouse VH 36-60 family member and human β 2-microglobulin (See, Table 2).

TABLE 2

Structure Values for Selected Additional Proteins						
Peptides	n	Average Background	Response per peptide	Number of epitope regions	Structure value	
hTpo	52	99	2.56	2.54	1	0.65
hIFN-B	52	88	3.17	2.79	1	0.75
Ber e 1	27	92	4.27	3.92	2	0.66
Mouse Vh 36-60 family	35	74	7.0	5.23	0	0.38
B2-microglobulin	36	87	3.9	3.39	0	0.39

[0194] Human IFN- β , Tpo and Ber e 1 are all known to induce immune responses in humans (See, Scagnolari et al., *J. Interferon Cytokine Res.*, 22:207-213 [2002]; and Sicherer and Sampson, *Curr. Opin. Pediatr.*, 12:567-573 [2000]; and Li et al., *Blood* 98:3241-3248 [2001]). The structure values for IFN- β , Tpo and Ber e 1 are all comparatively high. The value for the mouse VH region is comparatively low, suggesting that this protein is comparatively non-immunogenic. This result is consistent with a structural analysis of potential immunogenicity of the mouse heavy chain families (See, Olsson et al., [1991] supra). In addition, the result for β 2-microglobulin is low, consistent with tolerance induction to this ubiquitously expressed protein [Guery et al., [1995] supra).

Example 5

Population-Based Immune Responses

[0195] In this Example, experiments conducted to assess the population-based immune responses of a population are described. The donor bloods were obtained from Stanford

and Sacramento, as indicated above, as this population has a distribution that is not statistically different from the general "Caucasian" population in the U.S. Samples from the these donor bloods were tested in the I-MUNE® assay system described above. The structure values were calculated and collated for every protein tested in the I-MUNE® assay, for which there were more than two responses per peptide. The proteins tested were Ber e 1 (Brazil nut allergen), scFv (single-chain V region of an antibody; the VH and VL segments); BLA (β -lactamase); IFN-B (interferon-beta), FNA (subtilisin—BPN[®] Y217L), α -amylase, eglin (leech protease inhibitor; GenBank Accession No. CAA25380); RECK (human protease inhibitor; actually a small domain within the 971 amino acid RECK protein [GenBank Accession No. NP_066934] was tested; staphylokinase, TPO (human thrombopoietin), ecotin (serine protease inhibitor from *E. coli* K12; GenBank Accession No. NP_416713; ALCALASE® enzyme, savinase, human β -2 microglobulin, sTNFR1 (soluble tumor necrosis factor receptor 1). The results of these experiments are shown in Table 3. In this Table, the data indicate how many donors responded (i.e., mounted a proliferative response with an SI>2.95) to each peptide in the pepset.

TABLE 3

Test Protein	Results		
	Structure Value	Response/Peptide	Background %
Ber e 1	0.66	3.93	4.26
scFv	0.39	3.96	4.9
BLA	0.56	2.62	3.27
IFN-B	0.75	2.79	3.17
FNA	0.65	3.61	3.65
Amylase	0.81	2.29	2.79
Eglin	0.43	4.9	5.57
RECK	0.39	4.1	4.64
Staphylokinase	0.44	4.48	6.22
Tpo	0.65	2.24	2.53
Ecotin	0.64	3.98	5.69
Alcalase	0.72	2.16	2.35
GG36	0.65	2.24	3.45
β -2 microglobulin	0.39	3.38	3.9
sTNFR1	0.47	2.9	4.2

Example 6

Creation of Variants with Reduced Structure Values

[0196] In this Example, methods for the creation of variants with reduced structural values are provided. As an example of how the structure analysis finds use, in calculating the overall immunogenicity of variant proteins designed to reduce immunogenicity in humans, a structure value was calculated for a variant where the prominent responses to amino acids 70-84 and 109-123 in BPN[®] Y217L were reduced to background level responses. A limited dataset of 48 individuals was tested using peptide variants to the 70-84 and 109-123 regions of BPN[®] Y217L. Responses to the variants were found to be at background level. The complete dataset of 113 individuals was modified for structure calculations by reducing the responses to 70-84 and 109-123 to background levels. The structure was calculated this way in order to predict what the structure value would have been if 113 individuals had been tested along with the parent molecule. Since responses were removed from the calculation, an equivalent number of responses were scattered randomly through the dataset in order to maintain the same overall rate of response. The structure value for the modified protein variant was calculated to be 0.40 (See, Table 4).

TABLE 4

Structure Calculations for a Potential Protease Variant		
Protease	Prominent Epitope	Structure Value
BPN [®] Y217L	2	0.53
BPN [®] variant	0	0.40

[0197] In addition, in vitro data indicated that the protease variant with the lower structure value induced less proliferation. In these experiments, PMBC from thirty community donors were tested parametrically with either the whole protein parent enzyme (BPN[®] Y217L) or the variant protease. The enzymes were inactivated, and tested over a dose range from 5 to 40 ug/ml. The highest SI values reached for each protein are shown in FIG. 9. The parent protease had a structure value of 0.53, and the variant had a structure value of 0.40. The difference between optimal SI values for the two proteins tested on these thirty donors was significant, with a two-tailed parametric t-test value of $p < 0.01$. These results indicate that reducing the structure value from 0.53 to 0.40 has a profound effect on the in vitro antigenicity of the molecule.

[0198] In preferred methods of the present invention, when variant proteins are compared to a parent protein either in vitro or in vivo, the proteins are preferably compared at the same dose, in the formulation, in a matched set of donors and over the same dose curve. The variant proteins should retain the parent protein's general physical and structural properties, such as stability and activity. Additionally, the structure analysis precludes any processing differences between the parent protein and its variants.

Example 7

Designation of CD4+ T-cell Epitopes

[0199] In this Example, data from unexposed and exposed donors are presented. These data are provided in addition to those in the above Examples.

Unexposed Donors

[0200] Sixty-five donors were tested with a set of 15-mer peptides synthesized to cover the sequence of *B. lentus* sub-

tilisin. The percent response to each peptide for the 65 donors is shown in FIG. 11. A prominent response at position #54, corresponding to amino acids 160-174 is apparent. Another region of prominence is also apparent at peptide positions 23 and 31 (amino acids 67-81 and 91-105). The frequency of responses to the peptides in the set is shown in FIG. 12. It is clear that the frequency of responses to the peptide at amino acids 160-174 is different than the frequency of responses to other peptides in the set. However, the significance of the responses at amino acids 67-81 and 91-105 must be determined. Significance was determined by establishing Poisson distributions for the frequency data then determining the probability that a dataset containing the number of values represented by the number of peptides in the set would include as its highest member the value in question. For the peptide represented by amino acids 160-174, this probability was $p = 0.0004$. For the other two peptides, the probability was $p = 0.50$.

[0201] As a test of the epitope selection criteria, a set of seven donors verified to have been exposed to *B. lentus* subtilisin by skin-prick testing were also tested using the I-MUNE[®] assay system described herein. The number of responses at each peptide is shown for all seven donors (See FIG. 13). Only one peptide was found to elicit more than two responses. The three responders to the amino acids 163-177 peptide included both of the HLA-DR2(15) positive donors. An association with response to this peptide and HLA-DR2 (15) was noted previously (Stickler et al., J. Immunother., 23:654-660-[2000]). There were two donors that responded to six peptide regions, including the 67-81-region. No other peptide from the exposed donor data was prominent in the unexposed donor data. The 67-81 region has high homology (14/15 amino acid identity) to a known CD4+ T cell epitope in a related protease, and half of these donors were also SPT+ to this second protease. Therefore, as a conservative estimate one verified epitope was found in the unexposed donor population, and this epitope is found to be prominent in a set of epitopes recognized by verified protein-exposed donors.

[0202] Similar results were observed for another related subtilisin from *B. amyloliquifaciens*. Two prominent epitope regions that were highly significant were described, and these two epitopes were also found in a set of verified SPT+ donors (data not shown). As above, more prominent epitope regions were seen in compiled data from exposed donors, and the epitope peptides defined in the unexposed donor set were a subset of these.

Memory Responses

[0203] The I-MUNE[®] assay described above was performed on a set of peptides derived from the sequence of staphylokinase. Staphylokinase was selected for these experiments due to the fact that the general population accumulates specific responses to this protein over time (See, Warmerdam et al., J. Immunol., 168:155-161 [2002]). A set of 72 community donors was tested in the I-MUNE[®] assay system of the present invention with this protein. The responses to peptides in the staphylokinase set are shown in FIG. 14, Panel A. There are no clearly prominent responses in the staphylokinase data set. This is clearly shown in the frequency data (See, FIG. 4, Panel B) where, unlike the frequency data for *B. lentus* subtilisin, there are no individual peptides that accumulated responses at a rate that was clearly distinct from the distribution of responses to the other peptides. However, the prominent response rates at positions 5 (amino acids 13-27), 20 and

21 (amino acids 58-75), 29 (amino acids 85-99) and 36 (amino acids 106-120) are of interest. The dataset shows an average response of 4.48 responses per peptide (background=6.22%; See, Table 5, below). If this value is used to define the median of a Poisson distribution, a less conservative analysis indicates that the response frequencies displayed by all of the prominent peptides outlined above are significant ($p < 0.05$). This analysis is much less conservative than the analysis used to assign significance to epitopes found in the unexposed donors, as the Poisson distribution is defined by the median background value, and difference from this value is used to determine significance.

epitopes found using the less conservative epitope designation described and the published epitopes was excellent. In addition, the HLA associations reported are consistent between the two datasets (See, FIG. 15).

Negative Control

[0207] As a negative control, human β 2-microglobulin was also, tested in the I-MUNE® assay with samples from 87 community donors. This protein was selected as a negative control as it is present as part of the HLA class I molecule on the surface of all somatic cells. In addition, β 2-microglobulin

TABLE 5

Background Values for Proteins with Presumed Donor Pre-exposure					
	Donors tested	Expected responses/peptide ^b	Responses/peptide found ^c	Background +/- sd ^d	t-test ^e
11 industrial enzymes	n.a. ^a	n.a.	n.a.	3.15 +/- 1.57	n.a.
Ber e 1	92	2.77	3.92	4.26 +/- 4.05	P = 0.22
Staphylokinase	72	2.17	4.48	6.22 +/- 3.47	P = 0.0001
IFN-beta	88	2.65	2.79	3.17 +/- 3.28	n.d. ^f
Tpo	99	2.99	2.51	2.54 +/- 2.23	n.d.
TNF-R1	69	2.08	1.54	2.23 +/- 1.95	n.d.

[0204] In this Table, “a” indicates “not applicable”; “b” indicates the expected number of responses per peptide for the number of donors tested, based on the data from the 11 industrial proteins shown in FIG. 11; “c” indicates the response per peptide value determined experimentally for the protein tested; “d” indicates the background response value for the protein tested; “e” indicates the two-tailed, unequal variance t-test comparing the background values for the 11 industrial enzymes to the background, response of the protein tested; and “f” indicates “not determined.”

[0205] The five epitope peptides identified in the I-MUNE® assay were compared to published epitopes defined using cloned CD4+ T cell lines from donors with antigen-specific responses to staphylokinase (See, FIG. 15).

[0206] The regions defined using cloned T cells from 10 donors, D1, F2, C3, and D4 contain core sequences (common peptide sequence between the majority of the responding clones) that correspond to I-MUNE® assay-identified peptides 5, 20, 21 and 36 respectively. The I-MUNE® assay identified an epitope peptide at position 29 (amino acids 85-99) that was not detected using CD4+ T cell clones. This peptide associated with the presence of HLA-DR5(11). Only one donor who provided clones for the CD4+ T cell clone study carried this allele, and therefore it may have been missed. Alternatively, this peptide may not be processed from staphylokinase, and the result would therefore be a false positive within the I-MUNE® assay dataset. However, the carboxy terminus of the protein, region A5, was previously reported as being recognized by T cell clones (See, Warner-dam et al., supra). The I-MUNE® assay located an epitope in a subset of the region, peptide 36, which corresponded with the adjacent D4 region. Overall, the alignment between the

is expressed in the thymus during T cell development. Both central and peripheral tolerance mechanisms should affect the T cell repertoire, removing any CD4+ T cell with significant cross-reactivity to β 2-microglobulin-derived peptides (See, Guery et al., J. Immunol., 154:545-554 [1995]). Finally, there is minimal allelic variation in this molecule. One allelic variant was found in a database search (not shown). The results are shown in FIG. 16. The average background response to β 2-microglobulin was 3.90 +/- 1.82 percent. The percent responses to the peptides are shown in FIG. 16, Panel A, and the frequency of responses is shown in FIG. 16, Panel B. None of the peptide responses were significant based on the statistical method for an unexposed donor population with a low background response rate.

Reproducibility of Response Rates

[0208] The reproducibility of epitope peptide responses was determined by repeat testing of epitope peptides. Peptides were synthesized at least twice and were tested on multiple discrete groups of donors. The donor number tested for each test ranged from 27 to 103 donors. The average percent responses to the peptides were compared. The results are shown in Table 6. The average coefficient of variance (CV) for the four epitope peptides was 20%, and the median value was 21%. The range of CVs was 9.3 to 27%. These values compare favorably to other human cell-based ex vivo assays (Keilholz et al., J. Immunother., 25:97-138 [2000]; and Asai et al., Clin. Diagn. Lab. Immunol., 7:145-154 [2000]). In Table 6, “s.d.” is standard deviation, “s.e.” is standard error, and “s.d./average*100” is the percent CV. The average and the median values for the four peptides are shown.

TABLE 6

Reproducibility of Epitope Peptide Responses					
	Number of tests	Average	s.d.	s.e.	% CV
IFN-B	3	16.41	1.53	0.88	9.32
TPO	3	9.18	1.83	1.06	19.99
BPN ^Y Y217L #24	4	11.69	2.71	1.35	23.18
BPN ^Y Y217L#37	4	12.91	3.51	1.76	27.19
				Average for all	19.92
				Median	21.59

Epitopes Confirmed with Binding Studies

[0209] The IC₅₀ for HLA class II protein binding was determined for peptide epitopes defined by the in two related industrial bacterial proteases (See, FIG. 17). The peptides were tested in a competition assay for binding to 18 different HLA-DR and -DQ proteins. The prominent epitope in *B. lentus* subtilisin was found to bind a range of HLA-DR and -DQ molecules in two different frames (160-174 and 157-171), indicating promiscuous binding. Peptide binding to HLA-DR2(15) was found to be excellent, with an IC₅₀ of 127 nM. Only HLA-DR1 displayed a lower IC₅₀ value. Of the two epitopes defined by the I-MUNE[®] assay in *B. amyloliquificiens* subtilisin BPN^YY217L, the second epitope (amino acids 109-123) was found to be promiscuous in both the HLA analysis and in the binding analysis described in this Example. The first epitope (amino acids 70-84) also binds most HLA class II molecules tested, but it binds HLA-DR6(13) with an IC₅₀ of 0.69 nM. This likely explains the association seen in the data for a response to this peptide with HLA-DR6(13) donors (p=0.00015; relative risk=7.22, n=113 donors tested). Those results with values less than 500 nM were considered to be good binders and are highlighted in bold in FIG. 17. Also, in this Figure, degeneracy indicates the number of HLA Class II proteins that bind with an IC₅₀ of less than 500 nM out of the 18 total alleles tested.

Example 8

Identification of T-Cell Epitopes in Beta-Lactamase

[0210] Peptides for use in the I-MUNE[®] assay described in Example 9 were prepared based on the sequence of beta-lactamase precursor (cephalosporinase) obtained from *Enterobacter cloacae*, GenBank Accession No. P05364, with the sequence:

(SEQ ID NO: 1)

TPVSEKQLAE VVANTITPLM KAQSVPGMAV AVIYQGKPHY YTFGKADIAA

NKPVTPQTLE ELGSISKTFE GVLGGDAIAR GEISLDDAVT RYWPQLTGKQ

WQGIRMLDLA TYTAGGLPLQ VPDEVTDNAS LLRFYQNWQP QWKPGTTRLY

ANASIGLFGA LAVKPSGMPY EQAMTTRVLK PLKLDHTWIN VPKAEAAHYA

WGYRDGKAVR VSPGMLDAQA YGVKTNVQDM ANWVMANMAP ENVADASLKQ

GIALAQSRYW RIGSMYQGLG WEMLNWPVEA NTVVEGSDSK VALAPLPVAE

VNPPAPPVKA SWVHKTGSTG GFGSYVAFIP EKQIGIVMLA NTSYPNPARV

EAAYHILEAL Q.

[0211] Based upon the full length amino acid sequence (SEQ ID NO:1) of this beta-lactamase, a set of 15 mers off-set by three amino acids comprising the entire sequence of beta-lactamase were synthetically prepared by Mimotopes.

[0212] Peptide antigen was prepared as a 2 mg/ml stock solution in DMSO. First, 0.5 microliters of the stock solution were placed in each well of the 96 well plate in which the differentiated dendritic cells were previously placed. Then, 100 microliters of the diluted CD4+ T-cell solution as prepared above, were added to each well. Useful controls include diluted DMSO blanks, and tetanus toxoid positive controls.

[0213] The final concentrations in each well, at 20 microliter total volume are as follows:

[0214] 2×10⁴ CD4+

[0215] 2×10⁵ dendritic cells (R:S of 10:1)

[0216] 5 μM peptide

Example 9

I-MUNE[®] Assay for the Identification of Peptide T-Cell Epitopes in Beta-Lactamase Using Human T-Cells

[0217] Once the assay reagents (i.e., cells, peptides, etc.) were prepared and distributed into the 96-well plates, the I-MUNE[®] assays were conducted. Controls included dendritic cells plus CD4+ T-cells alone (with DMSO carrier) and with tetanus toxoid (Wyeth-Ayerst), at approximately 5 Lf/mL.

[0218] Cultures were incubated at 37° C. in 5% CO₂ for 5 days. Tritiated thymidine (NEN) was added at 0.5 microCi/well. The cultures were harvested and assessed for incorporation the next day, using the Wallac TriBeta scintillation detection system (Wallace Oy).

[0219] All tests were performed at least in duplicate. All tests reported displayed robust positive control responses to the antigen tetanus toxoid. Responses were averaged within each experiment, then normalized to the baseline response. A positive event (i.e., a proliferative response) was recorded if the response was at least 2.95 times the baseline response.

[0220] The immunogenic responses (i.e., T-cell proliferation) to the prepared peptides from beta-lactamase were tallied and are shown in FIG. 18. The overall background rate of responses to this peptide set was 4.04% for the donors tested. Using these methods various peptides of potential interest were identified, including those in Table 7, below.

TABLE 7

Peptides of Interest in Beta-Lactamase		
Peptide #	Sequence	SEQ ID NO:
6	ITPLMKAQSVPGMAV	2
36	MLDLATYTAGGLPLQ	3
49	GTTRLYANASIGLFG	4
107	TGGFGSYVAFLPEKQ	5

[0221] Peptides #36 and #107 were determined to be significant ($p < 0.05$), by both conservative ((1-EXP(-peptide number*(1-POISSON(value, mean, cumulative)))) and non-conservative (1-POISSON(value mean, cumulative)) statistical methods (these are Excel® spreadsheet formulae). The responses to these peptides were both 3x above the background (the response was 12.11%), and background+3 standard deviations (sd=2.87%, 3 sd=12.62%). Peptides #6 and #49 both reached statistical significance using less conservative analyses ($p < 0.05$ for both). The statistical analyses used are those described above.

[0222] As further described herein, it is contemplated that amino acid modifications in or around these peptides will provide variant beta-lactamases suitable for use as hypo-allergenic/immunogenic beta-lactamases.

Example 10

HLA Association with an Epitope Peptide Number

[0223] The HLA-DR and DQ expression of 65 of the donors tested in both rounds of assay testing described above were assessed using a commercially available PCR-based HLA typing kit (Bio-Synthesis). The phenotypic frequencies of individual HLA-DRB1 and DQB1 antigens among responders and non-responders to four epitopes (peptides #6, #36, #49, and #107) were tested using a chi-squared analysis with 1 degree of freedom. Wherever the HLA antigen was present in both reactive and non-reactive donors, a relative risk (i.e., the increased or decreased likelihood of presenting a reaction conditioned on the presence of the HLA antigen) was computed. Allele frequencies among donors that reacted and did not react to the specific epitopes were also computed. The effect of HLA antigens in the quantitative responses to peptides #6, #36, #49, and #107 were tested using a one-sided t-test. In addition, the mean and standard error of quantitative response for each peptide were determined.

[0224] In some embodiments, the phenotypic frequencies of individual HLA-DR and -DQ antigens among responders and non-responders to a peptide number are tested using a chi-squared analysis with 1 degree of freedom. The increased or decreased likelihood of reacting to an epitope corresponding to the peptide number is calculated wherever the HLA antigen in question is present in both responding and non-responding donor samples and the corresponding epitope is considered an HLA associated epitope.

[0225] The magnitude of the proliferative response to an individual peptide in responders and non-responders expressing epitope-associated HLA alleles were also analyzed. An "individual responder to the peptide" is defined by a stimulation index of greater than 2.95. It is contemplated that the proliferative response in donors who express an epitope asso-

ciated with HLA alleles are higher than in peptide responders who do not express the associated allele.

[0226] Statistically significant ($p < 0.05$) correlations were observed between some DR and DQ antigens and peptides #107, and #49. Although there were some differences in antigen carrier frequencies between responders and non-responders to peptides #36 and #6, these did not reach statistical significance. The strongest association was found between reaction to peptide #107 and the presence of DR8, with 33% in the reaction group, compared to 2% in the non-reaction group ($p < 0.0003$). The increased likelihood of a DR8+ individual relative to a DR8- individual to respond to this peptide was 7.63.

[0227] DR9 was increased among subjects reactive to epitope #49, with 28.6% in the reaction group and 3.4% in the non-reaction group ($p < 0.009$). The relative risk was found to be 6.1.

[0228] DR1 was associated with responses to one or more peptides, although none were statistically significant (26% in the reaction group and 9% in the non-reaction group; $p < 0.07$). DR1 was found to be increased among donors who responded to one or more of all four peptides (26% vs. 9%), although the difference did not reach statistical significance ($p < 0.07$; with a relative risk of 1.71). As DR1 was found to be associated with a higher quantitative response among responders to peptides #36 and #107, it is contemplated that this epitope may be involved in the risk of allergy to beta-lactamase. Although not quite statistically significant, it is of interest that DR1 was associated with a 27% increased quantitative response among donors reactive to peptide #107 (5.4 compared to 4.2). For peptide #36, DR1+ responders had a 76% (7.8 compared to 4.42) higher response, relative to DR1- responders, although the presence of this allele has not been found to be significantly associated with response to this or any other peptide.

[0229] Among the non-responders to peptide #107, DR13 was found to be associated with a particularly low response, as it was found to be 23% lower than the other genotypes.

[0230] The presence of DR13, but absence of DQ6 (i.e., DR13+ and DQ6-) was significantly associated with responses to at least two peptides (37% compared to 9%; $p < 0.028$), which is statistically significant. The relative risk for this combination was found to be 3.98. For the combination of DR13+ and DQ6-, was increased among responders to at least one of the 5 peptides ($p < 0.14$). DR13 appears to have an important role in allergy to beta-lactamase, but only in haplotypes that do not carry DQ6.

[0231] Indeed, DQ6 was completely absent from among donors responding to peptide #107, yet was found in 37.5% of non-responders ($p < 0.03$). The combination of DR13+ and DQ6- was increased, although not significantly among responders to peptide #49 (28% compared to 10%).

[0232] DQ4 was increased among individuals that reacted to peptide #36 (22% compared to 7%; $p < 0.15$), but this difference did not reach statistical significance. For peptide #6, although no allele was significantly associated with this peptide, DR4 was increased among donors who responded to this peptide (57% reactive, compared to 26% non-reactive; $p < 0.09$), with an associated relative risk of 3.5.

[0233] The presence of DR1 was found to correlate with a higher quantitative response (compared with other genotypes) among responsive donors to peptides #107 (27%) and #36 (36%). Although individually, DR1 was not associated

with any specific allele, taken together, these findings indicate that DR1 may be important in defining the response to beta-lactamase.

[0234] From the above, it is clear that the present invention provides methods and compositions for the identification of T-cell epitopes in wild-type beta-lactamase. Once antigenic epitopes are identified, the epitopes are modified as desired, and the peptide sequences of the modified epitopes incorporated into a wild-type beta-lactamase, so that the modified sequence is no longer capable of initiating the CD4⁺ T-cell response or wherein the CD4⁺ T-cell response is significantly reduced in comparison to the wild-type parent. In particular, the present invention provides means, including methods and compositions suitable for reducing the immunogenicity of beta-lactamase.

Example 11

Critical Residue Testing

[0235] In this Example, critical residue testing experiments for variants of peptides #6, #36, #49, and #107. In these experiments, alanine scans were performed for each peptide in order to produce variants of each of the parent peptides (i.e., peptides #6, #36, #40 and #107). These variant peptides were synthesized by Mimotopes (San Diego, Calif.) using the multi-pin synthesis technique known in the art (See e.g., Maeji et al., J. Immunol. Meth., 134:23-33 [1990]).

[0236] The assay was performed as described in Example 10, utilizing the variant peptides on a set of 66 donor samples. Proliferative responses were collated, and the results described in greater detail below.

[0237] For peptide #6 (SEQ ID NO:2), the following sequences in Table 8 were tested. Of these, sequences #6 and #7 (SEQ ID NOS:10 and 11) were found to be of interest. The results of the assay with these peptide variants are shown in FIG. 19.

TABLE 8

Peptide #6 and Variants		
Sequence #	Sequence	SEQ ID NO:
parent	ITPLMKAQSVPGMAV	2
2	ATPLMKAQSVPGMAV	6
3	IAPLMKAQSVPGMAV	7
4	ITALMKAQSVPGMAV	8
5	ITPAMKAQSVPGMAV	9
6	ITPLMKAQSVPGMAV	10
7	ITPLMKAQSVPGMAV	11
8	ITPLMKAASVPGMAV	12
9	ITPLMKAQAVPGMAV	13
10	ITPLMKAQSAVPGMAV	14
11	ITPLMKAQSVAGMAV	15
12	ITPLMKAQSVPAMAV	16
13	ITPLMKAQSVPGAAV	17
14	ITPLMKAQSVPGMAA	18

[0238] For peptide #36 (SEQ ID NO:3), the following sequences in Table 9 were tested. Of these, sequences #3, #4 and #8 (SEQ ID NOS:20, 21, and 25) were found to be of

interest. The results of the assay with these peptide variants is shown in FIG. 20.

TABLE 9

Peptide #36 and Variants		
Sequence #	Sequence	SEQ ID NO:
parent	MLDLATYTAGGLPLQ	3
2	ALDLATYTAGGLPLQ	19
3	MRLATYTAGGLPLQ	20
4	MLALATYTAGGLPLQ	21
5	MLDAATYTAGGLPLQ	22
6	MLDLAAYTAGGLPLQ	23
7	MLDLATATAGGLPLQ	24
8	MLDLATYTAGGLPLQ	25
9	MLDLATYTAAGLPLQ	26
10	MLDLATYTAGALPLQ	27
11	MLDLATYTAGGAPLQ	28
12	MLDLATYTAGGLALQ	29
13	MLDLATYTAGGLPAQ	30
14	MLDLATYTAGGLPLA	31

[0239] For peptide #49 (SEQ ID NO:4), the following sequences in Table 10 were tested. Of these, sequences, peptide 10 (SEQ ID NO:40) was found to be of interest. The results of the assay with these peptide variants is shown in FIG. 21.

TABLE 10

Peptide #49 and Variants		
Sequence	Sequence	SEQ ID NO:
parent	GTTRLYANASIGLFG	4
2	ATTRLYANASIGLFG	32
3	GATTRLYANASIGLFG	33
4	GTARLYANASIGLFG	34
5	GTALYANASIGLFG	35
6	GTTRAYANASIGLFG	36
7	GTTRLAANASIGLFG	37
8	GTTRLYAAASIGLFG	38
9	GTTRLYANAASIGLFG	39
10	GTTRLYANASIGLFG	40
11	GTTRLYANASIGAFG	41
12	GTTRLYANASIGLAG	42
13	GTTRLYANASIGLFA	43

[0240] For this epitope, as described in the following Example, specific amino acid substitutions were tested in the I-MUNE® assay (see above) on an additional set of 69 donors along with the alanine scan mutagenized peptides. These peptides were tested as 15-mer peptides offset by 3 amino acids across the peptide sequence of beta-lactamase that encompasses epitope #49. These tests were performed in order to ensure that the amino acid variants did not introduce a de novo CD4+ T-cell epitope in another frame.

[0241] For peptide #107, the following sequences in Table 11 were tested. Of these, sequences 6, 7, 8, 10, and 11 (SEQ ID NOS: 48, 49, 50, 52, and 53) were found to be of interest. The results of the assay with these peptide variants is shown in FIG. 22.

TABLE 11

Peptide #107 and Variants		
Sequence #	Sequence	SEQ ID NO:
parent	TGGFGSYVAFIPEKQ	5
2	TAGFGSYVAFIPEKQ	44
3	TGAFGSYVAFIPEKQ	45
4	TGGAGSYVAFIPEKQ	46
5	TGGFASYVAFIPEKQ	47
6	TGGFGAYVAFIPEKQ	48
7	TGGFGSAVAFIPEKQ	49
8	TGGFGSYAAFPEKQ	50
9	TGGFGSYVAAIPEKQ	51
10	TGGFGSYVAFPAEKQ	52
11	TGGFGSYVAFIAEKQ	53
12	TGGFGSYVAFIPEAQ	54
13	TGGFGSYVAFIPEAQ	55
14	TGGFGSYVAFIPEKA	56

[0242] In view of the above information, the following peptides were selected as potential variant sequences to reduce the immunogenic potential of the beta-lactamase epitopes.

TABLE 12

Variant Sequences with Potentially Reduced Immunogenicity		
Epitope Peptide	Parent Sequence	Variant Sequence
#6	ITPLMKAQSVPGMAV (SEQ ID NO: 2)	ITPLAKAQSVPGMAV (SEQ ID NO: 10)
		ITPLMAAQSVPGMAV (SEQ ID NO: 11)
#36	MLDLATYTAGGLPLQ (SEQ ID NO: 3)	MADLATYTAGGLPLQ (SEQ ID NO: 20)
		MLALATYTAGGLPLQ (SEQ ID NO: 21)
		MLDLATYAAGGLPLQ (SEQ ID NO: 25)
#49	GTTRLYANASIGLFG (SEQ ID NO: 4)	GTTRLYANASFGLFG (SEQ ID NO: 59)
		GTTRLYANASLGLFG (SEQ ID NO: 69)
		GTTRSYANASIGLFG (SEQ ID NO: 84)
		GTTRLYANASAGLFG (SEQ ID NO: 40)
#107	TGGFGSYVAFIPEKQ (SEQ ID NO: 5)	TGGFGAYVAFIPEKQ (SEQ ID NO: 48)
		TGGFGSAVAFIPEKQ (SEQ ID NO: 49)
		TGGFGSYAAFPEKQ (SEQ ID NO: 50)
		TGGFGSYVAFPEKQ (SEQ ID NO: 52)
		TGGFGSYVAFIAEKQ (SEQ ID NO: 53)

Example 12

Modifications to Peptide #49

[0243] As indicated above, specific amino acid substitutions in peptide #49 were tested in the I-MUNE® assay (see above) on an additional set of 69 donors along with the alanine scan mutagenized peptides. These peptides were tested as 15-mer peptides offset by 3 amino acids across the peptide sequence of beta-lactamase that encompasses epitope #49. These tests were performed in order to ensure that the amino acid variants did not introduce a de novo CD4+ T-cell epitope in another frame.

[0244] The assay was conducted on the following set of peptides listed in Table 13:

TABLE 13

Peptide #49 Parent Series GTTRLYANASIGLFG (SEQ ID NO:2)		
Peptide #	Sequence	SEQ ID NO:
1	WKPGTTRLYANASIG	54
2	GTTRLYANASIGLFG	2
3	RLYANASIGLFGALA	55
4	ANASIGLFGALAVKP	56
5	SIGLFGALAVKPSGN	57

[0245] The results for these peptides are provided in FIG. 23. In this Figure, each peptide number corresponds to the respective peptides in Table 13. The parent peptide is indicated in Table 13 and FIG. 23 as peptide #2.

[0246] The assay was also conducted on the following set of peptides, in which the starting (i.e., the modified epitope) has the substitution I155F.

TABLE 14

Peptide #49 Series GTTRLYANASIGLFG (SEQ ID NO:59)		
Peptide #	Sequence	SEQ ID NO:
1	WKPGTTRLYANASFG	58
2	GTTRLYANASIGLFG	59
3	RLYANASIGLFGALA	60
4	ANASIGLFGALAVKP	61
5	SIGLFGALAVKPSGN	62

[0247] The results for these peptides are provided in FIG. 24. In this Figure, each peptide number corresponds to the respective peptides in Table 14. The modified epitope is indicated in Table 14 and FIG. 24 as peptide #2.

[0248] The assay was also conducted on the following set of peptides, in which the starting (i.e., the modified epitope) has the substitution I155V.

TABLE 15

Peptide #49 Series GTTRLYANASVGLFG (SEQ ID NO:63)		
Peptide #	Sequence	SEQ ID NO:
1	WKPGTTRLYANASFG	64
2	GTTRLYANASVGLFG	65
3	RLYANASVGLFGALA	66
4	ANASVGLFGALAVKP	67
5	SFGLFGALAVKPSGN	68

[0249] The results for these peptides are provided in FIG. 25. In this Figure, each peptide number corresponds to the respective peptides in Table 15. The modified epitope is indicated in Table 15 and FIG. 25 as peptide #2.

[0250] The assay was also conducted on the following set of peptides, in which the starting (i.e., the modified epitope) has the substitution I155L.

TABLE 16

Peptide #49 Series GTTRLYANASLGLFG (SEQ ID NO:69)		
Peptide #	Sequence	SEQ ID NO:
1	WKPGTTRLYANALFG	70
2	GTTRLYANALGLFG	71
3	RLYANALGLFGALA	72
4	ANALGLFGALAVKP	73
5	LFGLFGALAVKPSGN	74

[0251] The results for these peptides are provided in FIG. 26. In this Figure, each peptide number corresponds to the respective peptides in Table 16. The modified epitope is indicated in Table 16 and FIG. 26 as peptide #2.

[0252] As indicated in FIGS. 24-26, of these three changes, the I155V change increased the percent of responders to the modified epitope sequence. The I155F and I155L changes had little effect.

[0253] Three additional changes in epitope #49 were tested, T147Q, L149S and L149R. As shown in FIGS. 27-29, only L149S had an effect on the epitope response rate. These peptides were also tested as 3-mer offsets, as described above.

[0254] Thus, the assay was also conducted on the following set of peptides, in which the starting (i.e., modified epitope) has the substitution T147Q.

TABLE 17

Peptide #49 Series QNWQPQWKPGTQRLY (SEQ ID NO:75)		
Peptide #	Sequence	SEQ ID NO:
1	RFYQNWQPQWKPGTQ	76
2	QNWQPQWKPGTQRLY	77
3	QPQWKPGTQRLYANA	78
4	WKPGTQRLYANASIG	79
5	GTQRLYANASIGLFG	80

[0255] The results for these peptides are provided in FIG. 27. In this Figure, each peptide number corresponds to the respective peptides in Table 17. The modified epitope is indicated in Table 17 and FIG. 27 as peptide #5.

[0256] The assay was also conducted on the following set of peptides, in which the starting (i.e., the modified epitope) has the substitution L149S.

TABLE 18

Peptide #49 Series QPOWKPGTTRSYANA (SEQ ID NO:82)		
Peptide #	Sequence	SEQ ID NO:
1	QNWQPQWKPGTTRSY	81
2	QPOWKPGTTRSYANA	82
3	WKPGTTRSYANASIG	83
4	GTTRSYANASIGLFG	84
5	RSYANASIGLFGALA	85

[0257] The results for these peptides are provided in FIG. 28. In this Figure, each peptide number corresponds to the respective peptides in Table 18. The parent peptide is indicated in Table 18 and FIG. 28 as peptide #4.

[0258] The assay was also conducted on the following set of peptides, in which the starting (i.e., "parent" peptide) has the substitution L149R.

TABLE 19

Peptide #49 Series QPOWKPGTTRRYANA (SEQ ID NO:87)		
Peptide #	Sequence	SEQ ID NO:
1	QNWQPQWKPGTTRRY	86
2	QPOWKPGTTRRYANA	87
3	WKPGTTRRYANASIG	88
4	GTTRRYANASIGLFG	89
5	RRYANASIGLFGALA	90

[0259] The results for these peptides are provided in FIG. 29. In this Figure, each peptide number corresponds to the respective peptides in Table 19. The modified epitope is indicated in Table 19 and FIG. 29 as peptide #4.

Example 14

PBMC Proliferation Assay

[0260] In this Example, experiments conducted to assess the ability of beta-lactamase and epitope-modified beta-lactamase to stimulate PBMCs are described. All of the proteins were purified to approximately 2 mg/ml.

[0261] The blood samples used in these experiments were the same as described above (i.e., before Example 1). The PBMCs were separated using Lymphoprep, as known in the art. The PBMCs were washed in PBS and counted using a Cell Dyn® 3700 blood analyzer (Abbott). The cell numbers and differentials were recorded. The PBMCs were resuspended to 4×10^6 cells/ml, in a solution of heat-inactivated human AB serum, RPMI 1640, pen/strep, glutamine, and 2-ME. Then, 2 mls per well were plated into 24-well plates. Two wells were used as no-enzyme controls. Then, the unmodified beta-lactamase and modified beta-lactamases were added to the wells at a concentrations of 10 ug/ml, 20 ug/ml, and 40 ug/ml. The epitope-modified beta-lactamases tested were K21A/S324A (designated as "pCD1.1") and K21A/S324A/L149S (designated as "pCD08.3"). The K21A mutation corresponds to SEQ ID NO:10, while the S324A

mutation corresponds to SEQ ID NO:48, and the L149S mutation corresponds to SEQ ID NO:84. The S324 variant is in epitope #107, while K21A is in epitope #6, and L149S is in epitope #49. The plates were incubated at 37° C., in a 5% CO₂, humidified atmosphere for 6-7 days. On the day of harvest, the cells in each well were mixed and resuspended in the wells. Then, 8 aliquots of 100 ul from each well were transferred to a 96-well microtiter plate. To these wells, 0.25 uCi of tritiated thymidine were added. These plates were incubated for 6 hours, the cells harvested and counted. For analysis, the data for the eight replicates from each well were averaged. For the controls, the two wells were sampled to provide a total of 32 replicates. Each set of eight control wells was averaged, and the four average values were used to calculate a CV for each donor. SI values were calculated by dividing the average for each set of eight wells for each sample by the average CPM for the control well. The data were analyzed by creating a dataset representing the highest SI value achieved for each donor and each enzyme. A donor was considered to have responded if the highest SI value was greater than 1.99. A total of 26 donors were tested; the results are shown in FIG. 30, with the average SI in Panel A and the percent responders in Panel B.

[0262] The results indicated that both of these epitope-modified beta-lactamases (pCD1.1 and pCD08.3) induced less proliferation in fewer donors overall, as compared to the wild-type beta-lactamase. There was no difference between the two epitope-modified beta-lactamases, indicating that the modification at position 149 (L149S) did not contribute to an increased immunogenicity of beta-lactamase.

Example 13

Selection of An Appropriate In Vitro Concentration for PBMC Assay Screening

[0263] In this Example, experiments conducted to determine the appropriate in vitro concentration for screening using the PBMC assay of the present invention. Two bacterial enzymes were selected for determining the appropriate concentration of protein for routine testing. Both proteins have been described to induce immune responses in human subjects. Inhalation of the bacterial protease BPN'Y217L has been documented to induce IgE positively in industrial workers (Schweigert et al., Clin. Exp. Allergy 30:1511 [2000]). However, the general population is not significantly exposed to this protein (Sarlo et al., Toxicol. Sci., 72:229 [2003]; and Pepys et al., Clin. Allergy 3:143 [1973]). Therefore, it represents a protein with a high likelihood of inducing responses in human cell populations, but the average donor sample will be naïve for response to the protein.

[0264] A second bacterial protein, beta-lactamase (BLA), was selected as it also demonstrates an ability to induce immune responses in clinical trial subjects (Melton and Sherwood, J. Natl. Cancer Instit., 88:153 [1996]). However, the BLA molecule used here is derived from a bacterium that is unlikely to cause disease in humans and therefore the protein also represents a potentially immunogenic protein.

[0265] Community donor peripheral blood mononuclear cells (PBMC) samples were cultured with a range of concentrations of endotoxin-free protein. The protease was inactivated by prior treatment with PMSF, a serine protease inhibitor. For the BPN'Y217L dataset, 8 donors were tested with the protein range depicted in FIG. 31. For BLA, 26 donors were

tested. A positive response was collated is the stimulation index (SI) was greater than 1.99.

[0266] The percent responder for each concentration of enzyme is shown by the squares in FIG. 31. The average SI data for each enzyme concentration is shown by the darker diamonds. For both BPN'Y217L and BLA, the 20 ug dose gave the overall optimum response, in that the average SIs did not increase with increasing concentration and the percent of donors responding also did not increase.

Example 14

Selection of Positive and Negative Control Proteins

[0267] In this Example, experiments conducted to select suitable positive and negative control proteins are described. In order to test the validity and the sensitivity of the assay, a set of proteins were selected for testing. Proteins were selected for their demonstrated ability to induce an immune response in unexposed humans, for the presence of pre-existing immunity to the protein in a significant percent of community donors, and for a demonstrated inability to induce immune responses. The proteins selected for testing are shown below in Table 20:

TABLE 20

Proteins Tested		
Protein	Pos/neg	donor status
BPN'Y217L	positive	naïve
BLA	positive	naïve
Staphylokinase	positive	pre-exposed
Sweet Potato extract	negative	pre-exposed
Carrot extract	negative	pre-exposed
Human IFN-beta	positive	pre-exposed

[0268] Donors were tested with the control proteins at 20 ug/ml. All proteins were tested for endotoxin and contained less than 0.25 EU/ml of concentrated stock solution. Average SI values were calculated, and percent of donors responding (SI>1.99) are shown in FIG. 32. A correlation between percent responders and average SI was noted and is to be expected due to the method of calculating percent responder data. Proteins determined to be negative controls in Table 20 are shown in FIG. 32 as light-colored diamonds, while proteins with demonstrated ability to provoke immune responses in human subjects are shown as darker diamonds. These data show that a correlation exists between the known immunogenic potential of this set of proteins, the number of responders and the strength of the immune responses observed.

Example 15

Testing Epitope-Modified Proteins

[0269] In this Example, experiments conducted to test the PBMC assay verification method of the present invention are described. Proteins that have been specifically modified to remove I-mune® assay identified CD4+ T cell epitopes were tested in the assay. Two enzymes were tested in the I-mune® assay, and immunodominant CD4+ T cell epitopes were identified. Critical residue testing of the identified epitopes was performed and modified variants were created. Functional protein variants were expressed and purified, and tested parametrically in the proliferation assay. The parent molecules are shown in FIG. 33 as a dark square (FNA) and circle (BLA),

and the modified variants are shown as light square (FNA) and circles (BLA). As shown in FIG. 33, modification of immunodominant CD4+ T cell epitopes results in a sharp reduction in both the frequency of responses and the magnitude of the responses for these proteins.

Example 16

Correlation with Structure Index Values

[0270] In this Example, the correlations of the assay results and structure index are described. For the modified proteins shown in FIG. 3, the following structure values were calculated based on the I-MUNE® assay data for the parent, and theoretical I-MUNE® assay data for the epitope-substituted variants, as shown in Table 21. In this Table, "AAs" refers to amino acids.

TABLE 21

Parent and Variant Structure Index Values			
	SIV	# Epitopes removed	# AAs changed
FNA	0.53		
Variant (LA20)	0.4	1	1
BLA	0.47		
Variant "1"	0.42	2	2
Variant "2"	0.42	3	3

Example 17

Detection of Immunological Tolerance

[0271] In this Example, experiments conducted using food allergen extracts and the results are described. Food allergen extracts were tested in the PBMC proliferation assay as described above, in order to determine if the imprint of tolerance induction could be detected. The majority of adults do not have verifiable food allergies (1-2%; Woods [2002]). However, the incidence of food allergy is higher in children (approximately 5%). It is generally accepted that tolerance to

allergenic foods occurs gradually during development. The mechanism of tolerance induction is unclear, but has been proposed to involve the establishment of food allergen-specific regulatory cells. Therefore, food allergen tolerance could be detected as mediating "bystander suppression" on the control level of background proliferation.

[0272] In these experiments, food extracts of egg white, peanut, whole wheat, carrot, and sweet potato (all purchased from Greer, as indicated above) were tested. These extracts were resuspended in DPBS and the endotoxin was removed, as described above. Extract solutions were adjusted to 1-2 mg of protein per ml, and tested at 20 ug/ml in the PBMC assay. The allergenic potential of egg white, peanut and whole wheat were considered to be high, while the allergenic potential of carrot and sweet potato were considered to be low. Eighteen community donors were tested in the PBMC assay with these food extracts. The Stimulation Indices and percent response were compiled and graphed (See, FIG. 34). The average SI values for the food extracts with high allergenic potential (i.e., whole wheat, egg white and peanut) were all less than 1.0, indicating that bystander suppression of the control level of proliferation occurred. None of the 18 donors mounted a positive proliferative response (defined as an SI value greater than 1.99). The less allergenic food extracts (i.e., carrot and sweet potato), had modest effects on the control proliferation and one donor reached positively to the carrot extract.

[0273] All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which that are obvious to those skilled in molecular biology, immunology, formulations, and/or related fields are intended to be within the scope of the present invention.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 91

<210> SEQ ID NO 1

<211> LENGTH: 361

<212> TYPE: PRT

<213> ORGANISM: Enterobacter cloacae

<400> SEQUENCE: 1

```

Thr Pro Val Ser Glu Lys Gln Leu Ala Glu Val Val Ala Asn Thr Ile
1          5          10          15

Thr Pro Leu Met Lys Ala Gln Ser Val Pro Gly Met Ala Val Ala Val
20         25         30

Ile Tyr Gln Gly Lys Pro His Tyr Tyr Thr Phe Gly Lys Ala Asp Ile
35         40         45

Ala Ala Asn Lys Pro Val Thr Pro Gln Thr Leu Phe Glu Leu Gly Ser
50         55         60

Ile Ser Lys Thr Phe Thr Gly Val Leu Gly Gly Asp Ala Ile Ala Arg
65         70         75         80

```

-continued

Gly Glu Ile Ser Leu Asp Asp Ala Val Thr Arg Tyr Trp Pro Gln Leu
 85 90 95

Thr Gly Lys Gln Trp Gln Gly Ile Arg Met Leu Asp Leu Ala Thr Tyr
 100 105 110

Thr Ala Gly Gly Leu Pro Leu Gln Val Pro Asp Glu Val Thr Asp Asn
 115 120 125

Ala Ser Leu Leu Arg Phe Tyr Gln Asn Trp Gln Pro Gln Trp Lys Pro
 130 135 140

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly Ala
 145 150 155 160

Leu Ala Val Lys Pro Ser Gly Met Pro Tyr Glu Gln Ala Met Thr Thr
 165 170 175

Arg Val Leu Lys Pro Leu Lys Leu Asp His Thr Trp Ile Asn Val Pro
 180 185 190

Lys Ala Glu Glu Ala His Tyr Ala Trp Gly Tyr Arg Asp Gly Lys Ala
 195 200 205

Val Arg Val Ser Pro Gly Met Leu Asp Ala Gln Ala Tyr Gly Val Lys
 210 215 220

Thr Asn Val Gln Asp Met Ala Asn Trp Val Met Ala Asn Met Ala Pro
 225 230 235 240

Glu Asn Val Ala Asp Ala Ser Leu Lys Gln Gly Ile Ala Leu Ala Gln
 245 250 255

Ser Arg Tyr Trp Arg Ile Gly Ser Met Tyr Gln Gly Leu Gly Trp Glu
 260 265 270

Met Leu Asn Trp Pro Val Glu Ala Asn Thr Val Val Glu Gly Ser Asp
 275 280 285

Ser Lys Val Ala Leu Ala Pro Leu Pro Val Ala Glu Val Asn Pro Pro
 290 295 300

Ala Pro Pro Val Lys Ala Ser Trp Val His Lys Thr Gly Ser Thr Gly
 305 310 315 320

Gly Phe Gly Ser Tyr Val Ala Phe Ile Pro Glu Lys Gln Ile Gly Ile
 325 330 335

Val Met Leu Ala Asn Thr Ser Tyr Pro Asn Pro Ala Arg Val Glu Ala
 340 345 350

Ala Tyr His Ile Leu Glu Ala Leu Gln
 355 360

<210> SEQ ID NO 2
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Enterobacter cloacae

<400> SEQUENCE: 2

Ile Thr Pro Leu Met Lys Ala Gln Ser Val Pro Gly Met Ala Val
 1 5 10 15

<210> SEQ ID NO 3
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Enterobacter cloacae

<400> SEQUENCE: 3

Met Leu Asp Leu Ala Thr Tyr Thr Ala Gly Gly Leu Pro Leu Gln
 1 5 10 15

-continued

<210> SEQ ID NO 4
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Enterobacter cloacae

<400> SEQUENCE: 4

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 5
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Enterobacter cloacae

<400> SEQUENCE: 5

Thr Gly Gly Phe Gly Ser Tyr Val Ala Phe Ile Pro Glu Lys Gln
1 5 10 15

<210> SEQ ID NO 6
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 6

Ala Thr Pro Leu Met Lys Ala Gln Ser Val Pro Gly Met Ala Val
1 5 10 15

<210> SEQ ID NO 7
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 7

Ile Ala Pro Leu Met Lys Ala Gln Ser Val Pro Gly Met Ala Val
1 5 10 15

<210> SEQ ID NO 8
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 8

Ile Thr Ala Leu Met Lys Ala Gln Ser Val Pro Gly Met Ala Val
1 5 10 15

<210> SEQ ID NO 9
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 9

Ile Thr Pro Ala Met Lys Ala Gln Ser Val Pro Gly Met Ala Val
1 5 10 15

<210> SEQ ID NO 10

-continued

<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 10

Ile Thr Pro Leu Ala Lys Ala Gln Ser Val Pro Gly Met Ala Val
1 5 10 15

<210> SEQ ID NO 11
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 11

Ile Thr Pro Leu Met Ala Ala Gln Ser Val Pro Gly Met Ala Val
1 5 10 15

<210> SEQ ID NO 12
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 12

Ile Thr Pro Leu Met Lys Ala Ala Ser Val Pro Gly Met Ala Val
1 5 10 15

<210> SEQ ID NO 13
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 13

Ile Thr Pro Leu Met Lys Ala Gln Ala Val Pro Gly Met Ala Val
1 5 10 15

<210> SEQ ID NO 14
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 14

Ile Thr Pro Leu Met Lys Ala Gln Ser Ala Pro Gly Met Ala Val
1 5 10 15

<210> SEQ ID NO 15
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 15

Ile Thr Pro Leu Met Lys Ala Gln Ser Val Ala Gly Met Ala Val
1 5 10 15

-continued

<210> SEQ ID NO 16
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 16

Ile Thr Pro Leu Met Lys Ala Gln Ser Val Pro Ala Met Ala Val
1 5 10 15

<210> SEQ ID NO 17
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 17

Ile Thr Pro Leu Met Lys Ala Gln Ser Val Pro Gly Ala Ala Val
1 5 10 15

<210> SEQ ID NO 18
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 18

Ile Thr Pro Leu Met Lys Ala Gln Ser Val Pro Gly Met Ala Ala
1 5 10 15

<210> SEQ ID NO 19
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 19

Ala Leu Asp Leu Ala Thr Tyr Thr Ala Gly Gly Leu Pro Leu Gln
1 5 10 15

<210> SEQ ID NO 20
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 20

Met Ala Asp Leu Ala Thr Tyr Thr Ala Gly Gly Leu Pro Leu Gln
1 5 10 15

<210> SEQ ID NO 21
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 21

Met Leu Ala Leu Ala Thr Tyr Thr Ala Gly Gly Leu Pro Leu Gln

-continued

1	5	10	15
---	---	----	----

<210> SEQ ID NO 22
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 22

Met Leu Asp Ala Ala Thr Tyr Thr Ala Gly Gly Leu Pro Leu Gln
1 5 10 15

<210> SEQ ID NO 23
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 23

Met Leu Asp Leu Ala Ala Tyr Thr Ala Gly Gly Leu Pro Leu Gln
1 5 10 15

<210> SEQ ID NO 24
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 24

Met Leu Asp Leu Ala Thr Ala Thr Ala Gly Gly Leu Pro Leu Gln
1 5 10 15

<210> SEQ ID NO 25
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 25

Met Leu Asp Leu Ala Thr Tyr Ala Ala Gly Gly Leu Pro Leu Gln
1 5 10 15

<210> SEQ ID NO 26
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 26

Met Leu Asp Leu Ala Thr Tyr Thr Ala Ala Gly Leu Pro Leu Gln
1 5 10 15

<210> SEQ ID NO 27
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 27

-continued

Met Leu Asp Leu Ala Thr Tyr Thr Ala Gly Ala Leu Pro Leu Gln
1 5 10 15

<210> SEQ ID NO 28
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 28

Met Leu Asp Leu Ala Thr Tyr Thr Ala Gly Gly Ala Pro Leu Gln
1 5 10 15

<210> SEQ ID NO 29
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 29

Met Leu Asp Leu Ala Thr Tyr Thr Ala Gly Gly Leu Ala Leu Gln
1 5 10 15

<210> SEQ ID NO 30
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 30

Met Leu Asp Leu Ala Thr Tyr Thr Ala Gly Gly Leu Pro Ala Gln
1 5 10 15

<210> SEQ ID NO 31
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 31

Met Leu Asp Leu Ala Thr Tyr Thr Ala Gly Gly Leu Pro Leu Ala
1 5 10 15

<210> SEQ ID NO 32
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 32

Ala Thr Thr Arg Leu Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 33
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

-continued

<400> SEQUENCE: 33

Gly Ala Thr Arg Leu Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 34

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 34

Gly Thr Ala Arg Leu Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 35

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 35

Gly Thr Thr Ala Leu Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 36

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 36

Gly Thr Thr Arg Ala Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 37

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 37

Gly Thr Thr Arg Leu Ala Ala Asn Ala Ser Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 38

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 38

Gly Thr Thr Arg Leu Tyr Ala Ala Ala Ser Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 39

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 39

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ala Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 40
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 40

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Ala Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 41
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 41

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Ile Gly Ala Phe Gly
1 5 10 15

<210> SEQ ID NO 42
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 42

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Ile Gly Leu Ala Gly
1 5 10 15

<210> SEQ ID NO 43
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 43

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Ile Gly Leu Phe Ala
1 5 10 15

<210> SEQ ID NO 44
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 44

Thr Ala Gly Phe Gly Ser Tyr Val Ala Phe Ile Pro Glu Lys Gln
1 5 10 15

<210> SEQ ID NO 45
<211> LENGTH: 15

-continued

<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 45

Thr Gly Ala Phe Gly Ser Tyr Val Ala Phe Ile Pro Glu Lys Gln
1 5 10 15

<210> SEQ ID NO 46
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 46

Thr Gly Gly Ala Gly Ser Tyr Val Ala Phe Ile Pro Glu Lys Gln
1 5 10 15

<210> SEQ ID NO 47
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 47

Thr Gly Gly Phe Ala Ser Tyr Val Ala Phe Ile Pro Glu Lys Gln
1 5 10 15

<210> SEQ ID NO 48
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 48

Thr Gly Gly Phe Gly Ala Tyr Val Ala Phe Ile Pro Glu Lys Gln
1 5 10 15

<210> SEQ ID NO 49
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 49

Thr Gly Gly Phe Gly Ser Ala Val Ala Phe Ile Pro Glu Lys Gln
1 5 10 15

<210> SEQ ID NO 50
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 50

Thr Gly Gly Phe Gly Ser Tyr Ala Ala Phe Ile Pro Glu Lys Gln
1 5 10 15

-continued

<210> SEQ ID NO 51
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 51

Thr Gly Gly Phe Gly Ser Tyr Val Ala Ala Ile Pro Glu Lys Gln
1 5 10 15

<210> SEQ ID NO 52
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 52

Thr Gly Gly Phe Gly Ser Tyr Val Ala Phe Ala Pro Glu Lys Gln
1 5 10 15

<210> SEQ ID NO 53
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 53

Thr Gly Gly Phe Gly Ser Tyr Val Ala Phe Ile Ala Glu Lys Gln
1 5 10 15

<210> SEQ ID NO 54
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 54

Thr Gly Gly Phe Gly Ser Tyr Val Ala Phe Ile Pro Ala Lys Gln
1 5 10 15

<210> SEQ ID NO 55
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 55

Thr Gly Gly Phe Gly Ser Tyr Val Ala Phe Ile Pro Glu Ala Gln
1 5 10 15

<210> SEQ ID NO 56
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 56

Thr Gly Gly Phe Gly Ser Tyr Val Ala Phe Ile Pro Glu Lys Ala
1 5 10 15

-continued

<210> SEQ ID NO 57
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 57

Ser Ile Gly Leu Phe Gly Ala Leu Ala Val Lys Pro Ser Gly Asn
1 5 10 15

<210> SEQ ID NO 58
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 58

Trp Lys Pro Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Phe Gly
1 5 10 15

<210> SEQ ID NO 59
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 59

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Phe Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 60
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 60

Arg Leu Tyr Ala Asn Ala Ser Phe Gly Leu Phe Gly Ala Leu Ala
1 5 10 15

<210> SEQ ID NO 61
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 61

Ala Asn Ala Ser Phe Gly Leu Phe Gly Ala Leu Ala Val Lys Pro
1 5 10 15

<210> SEQ ID NO 62
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 62

-continued

Ser Phe Gly Leu Phe Gly Ala Leu Ala Val Lys Pro Ser Gly Asn
1 5 10 15

<210> SEQ ID NO 63
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 63

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Val Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 64
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 64

Trp Lys Pro Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Phe Gly
1 5 10 15

<210> SEQ ID NO 65
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 65

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Phe Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 66
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 66

Arg Leu Tyr Ala Asn Ala Ser Phe Gly Leu Phe Gly Ala Leu Ala
1 5 10 15

<210> SEQ ID NO 67
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 67

Ala Asn Ala Ser Phe Gly Leu Phe Gly Ala Leu Ala Val Lys Pro
1 5 10 15

<210> SEQ ID NO 68
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

-continued

<400> SEQUENCE: 68

Ser Phe Gly Leu Phe Gly Ala Leu Ala Val Lys Pro Ser Gly Asn
1 5 10 15

<210> SEQ ID NO 69
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 69

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Ser Leu Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 70
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 70

Trp Lys Pro Gly Thr Thr Arg Leu Tyr Ala Asn Ala Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 71
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 71

Gly Thr Thr Arg Leu Tyr Ala Asn Ala Leu Phe Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 72
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 72

Arg Leu Tyr Ala Asn Ala Leu Phe Gly Leu Phe Gly Ala Leu Ala
1 5 10 15

<210> SEQ ID NO 73
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 73

Ala Asn Ala Leu Phe Gly Leu Phe Gly Ala Leu Ala Val Lys Pro
1 5 10 15

<210> SEQ ID NO 74
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 74

Leu Phe Gly Leu Phe Gly Ala Leu Ala Val Lys Pro Ser Gly Asn
1 5 10 15

<210> SEQ ID NO 75

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 75

Gln Asn Trp Gln Pro Gln Trp Lys Pro Gly Thr Gln Arg Leu Tyr
1 5 10 15

<210> SEQ ID NO 76

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 76

Arg Phe Tyr Gln Asn Trp Gln Pro Gln Trp Lys Pro Gly Thr Gln
1 5 10 15

<210> SEQ ID NO 77

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 77

Gln Asn Trp Gln Pro Gln Trp Lys Pro Gly Thr Gln Arg Leu Tyr
1 5 10 15

<210> SEQ ID NO 78

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 78

Gln Pro Gln Trp Lys Pro Gly Thr Gln Arg Leu Tyr Ala Asn Ala
1 5 10 15

<210> SEQ ID NO 79

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 79

Trp Lys Pro Gly Thr Gln Arg Leu Tyr Ala Asn Ala Ser Ile Gly
1 5 10 15

<210> SEQ ID NO 80

<211> LENGTH: 15

<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 80

Gly Thr Gln Arg Leu Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 81
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 81

Gln Asn Trp Gln Pro Gln Trp Lys Pro Gly Thr Thr Arg Ser Tyr
1 5 10 15

<210> SEQ ID NO 82
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 82

Gln Pro Gln Trp Lys Pro Gly Thr Thr Arg Ser Tyr Ala Asn Ala
1 5 10 15

<210> SEQ ID NO 83
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 83

Trp Lys Pro Gly Thr Thr Arg Ser Tyr Ala Asn Ala Ser Ile Gly
1 5 10 15

<210> SEQ ID NO 84
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 84

Gly Thr Thr Arg Ser Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly
1 5 10 15

<210> SEQ ID NO 85
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 85

Arg Ser Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly Ala Leu Ala
1 5 10 15

<210> SEQ ID NO 86

-continued

<211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 86

Gln Asn Trp Gln Pro Gln Trp Lys Pro Gly Thr Thr Arg Arg Tyr
 1 5 10 15

<210> SEQ ID NO 87
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 87

Gln Pro Gln Trp Lys Pro Gly Thr Thr Arg Arg Tyr Ala Asn Ala
 1 5 10 15

<210> SEQ ID NO 88
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 88

Trp Lys Pro Gly Thr Thr Arg Arg Tyr Ala Asn Ala Ser Ile Gly
 1 5 10 15

<210> SEQ ID NO 89
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 89

Gly Thr Thr Arg Arg Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly
 1 5 10 15

<210> SEQ ID NO 90
 <211> LENGTH: 15
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 90

Arg Arg Tyr Ala Asn Ala Ser Ile Gly Leu Phe Gly Ala Leu Ala
 1 5 10 15

<210> SEQ ID NO 91
 <211> LENGTH: 4
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: synthetic variant

<400> SEQUENCE: 91

Ala Ala Pro Phe
 1

1. A method for assessing immune response profiles of animal populations comprising in operable combination the steps of:

- a) obtaining:
 - i) dendritic cells and CD4+ T-cells from an individual within said animal population,
 - ii) and at least one protein sequence of interest;
- b) producing peptides comprising fragments of said protein sequence of interest, such that the entire protein sequence of interest is encompassed in said fragments;
- c) differentiating said dendritic cells to produce differentiated dendritic cells;
- d) exposing said peptides to said CD4+ T-cells and said differentiated dendritic cells;
- e) assessing the proliferation response of said CD4+ T-cells to each peptide; and
- f) determining the stimulation index of said proliferation response of said CD4+ T-cells to each of said peptides;
- g) repeating steps a) to f) for at least one additional individual;
- h) comparing the results for said individual and said at least one additional individual, such that the immune response of multiple individuals is provided.

2. The method of claim 1, wherein a stimulation index of at least about 1.5 is recorded as positive.

3. The method of claim 1, wherein said animal population is a human population.

4. The method of claim 3, wherein the structure values of the responses observed for individuals within the population are determined.

5. The method of claim 4, wherein said steps a) through h) are repeated using at least one additional protein of interest.

6. The method of claim 5, wherein said structure values of the responses for said protein of interest and said at least one additional protein of interest are used to rank the relative immunogenicity of said protein of interest and said at least one additional protein of interest.

7. The method of claim 6, wherein the protein having the lower structure value is ranked as being less immunogenic than a protein having a higher structure value.

8. The method of claim 5, wherein said at least one additional protein of interest comprises said protein of interest that has been modified to produce a modified protein of interest.

9. The method of claim 8, wherein said modified protein of interest is selected from the group consisting of hypoimmunogenic proteins and hyperimmunogenic proteins.

10. The method of claim 8, wherein said modified protein of interest is produced by substituting at least one amino acid in said at least one additional protein of interest to produce a variant protein of interest.

11. The method of claim 6, wherein said protein of interest and said at least one additional protein of interest are selected from the group of proteins consisting of enzymes, antibodies, soluble receptors, fusion proteins, structural proteins, binding proteins, and hormones.

12. The method of claim 9, wherein said enzyme is selected from the group consisting of proteases, subtilisins, cytokines, lipases, cellulases, amylases, oxidases, isomerases, kinases, phosphatases, lactamases, and reductases.

13. The method of claim 1, further comprising a validation assay comprising a peripheral blood mononuclear cell response assessment.

14. A method for ranking the relative immunogenicity of a first protein and at least one additional protein, comprising the following steps in operable order:

- (a) preparing a first pepset from said first protein and preparing at least one additional pepset from each of said additional proteins,
- (b) obtaining solutions comprising dendritic cells and a solutions of naïve CD4+ and/or CD8+ T-cells, wherein each of said solutions is obtained from a first human blood source;
- (c) obtaining solutions comprising dendritic cells and a solutions of naïve CD4+ and/or CD8+ T-cells, wherein each of said solutions is obtained from at least one additional human blood source;
- (d) differentiating said dendritic cells from each of the human blood sources of steps (b) and (c), to produce solutions of differentiated dendritic cells for said human blood sources;
- (e) combining said solutions of differentiated dendritic cells and said naïve CD4+ and/or CD8+ T-cells from said human blood sources with a portion of said first pepset;
- (f) combining said solutions of differentiated dendritic cells and said naïve CD4+ and/or CD8+ T-cells with each of said pepsets from said additional proteins;
- (g) measuring proliferation of said T-cells in steps (e) and (f), to determine the responses to each peptide in said first and at least one additional pepset;
- (h) compiling the responses of the T-cells in step (g) for said first protein and said additional proteins;
- (i) determining the structure value of said compiled responses of step (h) for said first protein and said additional proteins; and
- (j) comparing the structure value obtained for said first protein with said structure value for said additional proteins to determine the immunogenicity ranking of said first protein and said additional proteins.

15. The method of claim 14, wherein said pepsets comprise peptides of about 15 amino acids in length.

16. The method of claim 15, wherein said peptides overlap each adjacent peptide by about 3 amino acids.

17. The method of claim 14, wherein the protein having the lowest structure value is ranked as being less immunogenic than the protein having the higher structure value.

18. The method of claim 14, wherein said protein of interest and said at least one additional protein of interest are selected from the group of proteins consisting of enzymes, antibodies, structural proteins, binding proteins, and hormones.

19. The method of claim 18, wherein said enzyme is selected from the group consisting of proteases, subtilisins, cytokines, lipases, cellulases, amylases, oxidases, isomerases, kinases, phosphatases, lactamases, and reductases.

20. The method of claim 14, wherein said at least one additional protein of interest comprises said protein of interest that has been modified to produce a modified protein of interest.

21. The method of claim 14, wherein said modified protein of interest is selected from the group consisting of hypoimmunogenic proteins and hyperimmunogenic proteins.

22. The method of claim 20, wherein said modified protein of interest is produced by substituting at least one amino acid in said at least one additional protein of interest to produce a variant protein of interest.

23. The method of claim **14**, wherein the protein having a stimulation index value of between about 2.7 and about 3.2 is considered to have a positive response.

24. The method of claim **14**, wherein the stimulation index values of said protein of interest and said at least one additional protein are compared.

25. The method of claim **14**, comprising the further step of categorizing said first protein and said second protein, based on the background percent response and the structure values obtained for each of said first and second proteins.

26. The method of claim **14**, further comprising a validation assay comprising a peripheral blood mononuclear cell response assessment.

27. A method for ranking the relative immunogenicity of two proteins, wherein the second protein is a protein variant of the first protein, comprising the following steps in operable order:

- (a) preparing a first pepset from said first protein and a second pepset from said second protein;
- (b) obtaining from a solution comprising dendritic cells and a solution of naïve CD4+ and/or CD8+ T-cells, wherein both of said solutions are obtained from a single blood source;
- (c) differentiating said dendritic cells to produce a solution of differentiated dendritic cells;
- (d) combining said solution of differentiated dendritic cells and said naïve CD4+ and/or CD8+ T-cells with said first pepset;
- (e) combining said solution of differentiated dendritic cells and said naïve CD4+ and/or CD8+ T-cells with said second pepset;
- (f) measuring proliferation of said T-cells in steps (d) and (e), to determine the responses to each peptide in the first and second pepsets;
- (g) compiling the responses obtained for said T-cells in step (f) for said first protein and said second protein;
- (h) determining the structure value of the compiled responses of step (g) for said first protein and said second protein;
- (i) comparing said structure value obtained for said first protein with said structure value for said second protein to determine the immunogenicity ranking of said first protein and said second protein.

28. The method of claim **27**, wherein said second protein is ranked as being less immunogenic than the said first protein.

29. The method of claim **27**, wherein said first protein is ranked as being less immunogenic than the said second protein.

30. The method of claim **27**, wherein said pepsets comprise peptides of about 15 amino acids in length.

31. The method of claim **30**, wherein said peptides overlap each adjacent peptide by about 3 amino acids.

32. The method of claim **27**, wherein said first protein is selected from the group of proteins consisting of enzymes, antibodies, structural proteins, binding proteins, and hormones.

33. The method of claim **27**, wherein said enzyme is selected from the group consisting of proteases, subtilisins, cytokines, lipases, cellulases, amylases, oxidases, isomerases, kinases, phosphatases, lactamases, soluble receptors, fusion proteins, and reductases.

34. The method of claim **27**, wherein said second protein comprises a reduction of at least one prominent region in said first protein.

35. The method of claim **27**, wherein the proliferation of said T-cells in step (f) for said first protein is at background level.

36. The method of claim **27**, wherein the proliferation of said T-cells in step (f) for at least one variant protein is at a background level.

37. The method of claim **27**, further comprising a validation assay comprising a peripheral blood mononuclear cell response assessment.

38. A method for determining the immune response of a test population against a test protein, comprising the following steps in operable order:

- (a) preparing a pepset from a test protein;
- (b) obtaining a plurality of solutions comprising human dendritic cells and a plurality of solutions of naïve human CD4+ and/or CD8+ T-cells, wherein said solutions of human dendritic cells and solutions of naïve human CD4+ and/or CD8+ T-cells are obtained from a plurality of individuals within said test population;
- (c) differentiating said dendritic cells to produce a plurality of solutions comprising differentiated dendritic cells;
- (d) combining said plurality of solutions of differentiated dendritic cells and said solutions of naïve CD4+ and/or CD8+ T-cells with said pepset, wherein each of said solutions of differentiated dendritic cells and naïve CD4+ and/or CD8+ T-cells are from one individual within said test population are combined;
- (e) measuring proliferation of said T-cells in step (d), to determine the responses to each peptide in said pepset;
- (g) compiling the responses of said T-cells in step (e) for said test protein;
- (h) determining the structure value of said compiled responses obtained in step (g) for said test protein; and
- (i) determining the level of exposure of said plurality of individuals to said test protein.

39. The method of claim **38**, wherein said pepsets comprise peptides of about 15 amino acids in length.

40. The method of claim **39**, wherein said peptides overlap each adjacent peptide by about 3 amino acids.

41. The method of claim **38**, wherein said test protein is selected from the group of proteins consisting of enzymes, antibodies, soluble receptors, fusion proteins, structural proteins, binding proteins, and hormones.

42. The method of claim **38**, wherein said enzyme is selected from the group consisting of proteases, subtilisins, cytokines, lipases, cellulases, amylases, oxidases, isomerases, kinases, phosphatases, lactamases, and reductases.

43. The method of claim **38**, wherein the exposure level of said plurality of individuals to said test protein is compared.

44. The method of claim **38**, further comprising at least one additional test protein.

45. The method of claim **44**, wherein said at least one additional test protein is obtained by modifying said test protein.

46. The method of claim **44**, wherein the background percent response and structure values of said test protein and said at least one additional test protein are categorized and/or ranked.

47. The method of claim **38**, further comprising a validation assay comprising a peripheral blood mononuclear cell response assessment.

专利名称(译)	基于人群的免疫应答测定预测方法和免疫应答数据验证方法		
公开(公告)号	US20080220450A1	公开(公告)日	2008-09-11
申请号	US10/591681	申请日	2005-04-25
[标]申请(专利权)人(译)	丹尼斯科美国公司		
申请(专利权)人(译)	DANISCO美国, INC., Genencor分部		
当前申请(专利权)人(译)	DANISCO美国, INC., Genencor分部		
[标]发明人	HARDING FIONA A		
发明人	HARDING, FIONA A.		
IPC分类号	G01N33/53 C12Q1/02 C12Q1/48 C12Q1/34 C12Q1/26 C12Q1/42 C12Q1/40 G01N33/50 G01N33/564		
CPC分类号	G01N33/505 G01N33/5047		
优先权	60/565680 2004-04-26 US		
外部链接	Espacenet USPTO		

摘要(译)

本发明提供了评估群体的免疫应答谱的方法。特别地, 本发明提供了定性评估人群免疫应答的方法, 其中分析了针对任何目的蛋白质的免疫应答。本发明进一步提供了基于蛋白质的相对免疫原性对蛋白质进行分级的方法。在进一步的实施方案中, 本发明提供了用于验证免疫应答数据的手段, 以及用于预测针对任何抗原/免疫原的免疫应答的手段。此外, 本发明提供了产生具有降低的免疫原性的蛋白质的方法, 用于各种应用。

